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A B S T R A C T
Background
Pain is a common feature of childhood and adolescence around the world, and for many young people, that pain is chronic. The
World Health Organization guidelines for pharmacological treatments for children’s persisting pain acknowledge that pain in children
is a major public health concern of high significance in most parts of the world. While in the past pain was largely dismissed and was
frequently left untreated, views on children’s pain have changed over time, and relief of pain is now seen as important.
We designed a suite of seven reviews on chronic non-cancer pain and cancer pain (looking at antidepressants, antiepileptic drugs, non-
steroidal anti-inflammatory drugs, opioids, and paracetamol) in order to review the evidence for children’s pain utilising pharmacological
interventions.
As the leading cause of morbidity in the world today, chronic disease (and its associated pain) is a major health concern. Chronic pain
(that is pain lasting three months or longer) can arise in the paediatric population in a variety of pathophysiological classifications
(nociceptive, neuropathic, or idiopathic) from genetic conditions, nerve damage pain, chronic musculoskeletal pain, and chronic
abdominal pain, as well as for other unknown reasons.
Non-steroidal anti-inflammatory drugs (NSAIDs) are used to treat pain, reduce fever, and for their anti-inflammation properties. They
are commonly usedwithin paediatric painmanagement.Non-steroidal anti-inflammatory drugs are currently licensed for use inWestern
countries, however they are not approved for infants under three months old. The main adverse effects include renal impairment
and gastrointestinal issues. Common side effects in children include diarrhoea, headache, nausea, constipation, rash, dizziness, and
abdominal pain.
Objectives
To assess the analgesic efficacy and adverse events of NSAIDs used to treat chronic non-cancer pain in children and adolescents aged
between birth and 17 years, in any setting.
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Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online, MEDLINE
via Ovid, and Embase via Ovid from inception to 6 September 2016. We also searched the reference lists of retrieved studies and
reviews, as well as online clinical trial registries.
Selection criteria
Randomised controlled trials, with or without blinding, of any dose and any route, treating chronic non-cancer pain in children and
adolescents, comparing any NSAID with placebo or an active comparator.
Data collection and analysis
Two review authors independently assessed studies for eligibility.We planned to use dichotomous data to calculate risk ratio and number
needed to treat for one additional event, using standard methods. We assessed GRADE and created three ’Summary of findings’ tables.
Main results
We included seven studies with a total of 1074 participants (aged 2 to 18 years) with chronic juvenile polyarthritis or chronic juvenile
rheumatoid arthritis. All seven studies compared an NSAID with an active comparator. None of the studies were placebo controlled.
No two studies investigated the same type of NSAID compared with another. We were unable to perform a meta-analysis.
Risk of bias varied. For randomisation and allocation concealment, one study was low risk and six studies were unclear risk. For blinding
of participants and personnel, three studies were low risk and four studies were unclear to high risk. For blinding of outcome assessors,
all studies were unclear risk. For attrition, four studies were low risk and three studies were unclear risk. For selective reporting, four
studies were low risk, two studies were unclear risk, and one study was high risk. For size, three studies were unclear risk and four
studies were high risk. For other potential sources of bias, seven studies were low risk.
Primary outcomes
Three studies reported participant-reported pain relief of 30% or greater, showing no statistically significant difference in pain scores
between meloxicam and naproxen, celecoxib and naproxen, or rofecoxib and naproxen (P > 0.05) (low-quality evidence).
One study reported participant-reported pain relief of 50% or greater, showing no statistically significant difference in pain scores
between low-dose meloxicam (0.125 mg/kg) and high-dose meloxicam (0.25 mg/kg) when compared to naproxen 10 mg/kg (P > 0.05)
(low-quality evidence).
One study reported Patient Global Impression of Change, showing ’very much improved’ in 85% of ibuprofen and 90% of aspirin
participants (low-quality evidence).
Secondary outcomes
All seven studies reported adverse events. Participants reporting an adverse event (one or more per person) by drug were: aspirin 85/
202; fenoprofen 28/49; ibuprofen 40/45; indomethacin 9/30; ketoprofen 9/30; meloxicam 18/47; naproxen 44/202; and rofecoxib
47/209 (very low-quality evidence).
All seven studies reported withdrawals due to adverse events. Participants withdrawn due to an adverse event by drug were: aspirin 16/
120; celecoxib 10/159; fenoprofen 0/49; ibuprofen 0/45; indomethacin 0/30; ketoprofen 0/30; meloxicam 10/147; naproxen 17/285;
and rofecoxib 3/209 (very low-quality evidence).
All seven studies reported serious adverse events. Participants experiencing a serious adverse event by drug were: aspirin 13/120; celecoxib
5/159; fenoprofen 0/79; ketoprofen 0/30; ibuprofen 4/45; indomethacin 0/30; meloxicam 11/147; naproxen 10/285; and rofecoxib
0/209 (very low-quality evidence).
There were few or no data for our remaining secondary outcomes: Carer Global Impression of Change; requirement for rescue analgesia;
sleep duration and quality; acceptability of treatment; physical functioning as defined by validated scales; and quality of life as defined
by validated scales (very low-quality evidence).
We rated the overall quality of the evidence (GRADE rating) for our primary and secondary outcomes as very low because there were
limited data from studies and no opportunity for a meta-analysis.
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Authors’ conclusions
We identified only a small number of studies, with insufficient data for analysis.
As we could undertake no meta-analysis, we are unable to comment about efficacy or harm from the use of NSAIDs to treat chronic
non-cancer pain in children and adolescents. Similarly, we cannot comment on our remaining secondary outcomes: Carer Global
Impression of Change; requirement for rescue analgesia; sleep duration and quality; acceptability of treatment; physical functioning;
and quality of life.
We know from adult randomised controlled trials that some NSAIDs, such as ibuprofen, naproxen, and aspirin, can be effective in
certain chronic pain conditions.
P L A I N L A N G U A G E S U M M A R Y
Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents
Bottom line
We are uncertain as to whether NSAIDs can provide pain relief for chronic non-cancer pain in children or adolescents.
Background
Children can experience chronic or recurrent pain related to genetic conditions, nerve damage, muscle or bone pain, stomach pain, or
from unknown reasons. Chronic pain is pain that lasts three months or longer and is commonly accompanied by changes in lifestyle
and functional abilities, as well as by signs and symptoms of depression and anxiety.
Non-steroidal anti-inflammatory drugs are used to treat pain or reduce fever, and are commonly used in children. They include over-
the-counter medications such as ibuprofen, aspirin, and naproxen, as well as prescription-only drugs. NSAIDs are currently licensed
for use in Western countries, but are not approved for infants under three months old. The key side effects of NSAIDs are kidney
failure and stomach problems. Other common side effects in children include diarrhoea, headache, nausea, constipation, rash, dizziness,
flatulence, stomach pain, and indigestion.
Study characteristics
In September 2016 we searched for clinical trials where NSAIDs were used to treat chronic pain. We found seven trials (with a total
of 1074 participants, aged 2 to 18 years) with chronic juvenile polyarthritis or chronic juvenile rheumatoid arthritis, which they had
for more than 3 months.
Key results
The studies looked at different comparisons of aspirin, celecoxib, fenoprofen, ibuprofen, indomethacin, ketoprofen, meloxicam,
naproxen, and rofecoxib. No studies compared NSAIDs with placebo. We could not compare these drugs, or the pain results, as the
studies all investigated different types of NSAIDs.
Side effects were common, with children reporting problems with aspirin (85 out of 202 participants), fenoprofen (28 out of 49),
ibuprofen (40 out of 45), indomethacin (9 out of 30), ketoprofen (9 out of 30), meloxicam (18 out of 47), naproxen (44 out of 202),
and rofecoxib (47 out of 209).
Quality of the evidence
We rated the quality of the evidence from studies using four levels: very low, low, moderate, or high. Very low-quality evidence means
that we are very uncertain about the results. High-quality evidence means that we are very confident in the results.
Overall, the evidence was very low quality due to a lack of data. As a result, we have no evidence to support or refute the use of NSAIDs
to treat chronic non-cancer pain in children and adolescents.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Meloxicam compared with naproxen for chronic non-cancer pain
Patient or population: children and adolescents with chronic non-cancer pain
Settings: mult icentre paediatric rheumatology tert iary care units (internat ional)
Intervention: meloxicam
Comparison: naproxen
Outcomes Illustrative comparative risks* (95%
CI)
Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Naproxen Meloxicam
Participant-
reported pain relief of
30% or greater
50/ 78 89/ 147 N/ A 225 part icipants
(1 study)
⊕⊕©©
low
© f or risk of bias
© f or imprecision
Participant-
reported pain relief of
50% or greater
39/ 78 70/ 147 N/ A 225 part icipants
(1 study)
⊕⊕©©
low
© f or risk of bias
© f or imprecision
Patient Global Impres-
sion of Change much or
very much improved
No data No data N/ A N/ A ⊕©©©
very low
No evidence to support or
refute* *
Any adverse event 10/ 78 18/ 147 N/ A 225 part icipants
(1 study)
⊕©©©
very low
Number of events too small
to be meaningful
Serious adverse event 10/ 78 11/ 147 N/ A 225 part icipants
(1 study)
⊕©©©
very low
Number of events too small
to be meaningful
Withdrawals due to ad-
verse events
10/ 78 10/ 147 N/ A 225 part icipants
(1 study)
⊕©©©
very low
Number of events too small
to be meaningful
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* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; N/A: not applicable
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate; the true ef fect is likely to be close to the est imate of ef fect, but there is a possibility that it is substant ially
dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited; the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate; the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
* * In circumstances where there were no data reported for an outcome, we report the level of evidence as ’very low’ with no evidence to support or refute
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Pain is a common feature of childhood and adolescence around the
world, and formany youngpeople, that pain is chronic. TheWorld
Health Organization guidelines for pharmacological treatments
for persisting pain in children acknowledge that pain in children
is a major public health concern of high significance in most parts
of the world (WHO 2012). While in the past, pain was largely
dismissed and was frequently left untreated, views on children’s
pain have changed over time, and relief of pain is now seen as
important. Since the 1970s, studies comparing child and adult
pain management have revealed a variety of responses to pain,
fuelling the need for a more in-depth focus on paediatric pain
(Caes 2016).
Infants (zero to 12 months), children (1 to 9 years), and adoles-
cents (10 to 18 years), WHO 2012, account for 27% (1.9 billion)
of the world’s population (United Nations 2015); the proportion
of those aged 14 years and under ranges from12% (inHongKong)
to 50% (in Niger) (World Bank 2014). However, little is known
about the painmanagement needs of this population. For example,
in the Cochrane Library, approximately 12 reviews produced by
the Cochrane Pain, Palliative and Supportive Care Review Group
in the past 18 years have been specifically concerned with chil-
dren and adolescents, compared to over 100 reviews specific to
adults. Additional motivating factors for investigating children’s
pain include the vast amount of unmanaged pain in the paediatric
population and the development of new technologies and treat-
ments. We convened an international group of leaders in paedi-
atric pain to design a suite of seven reviews in chronic pain and
cancer pain (looking at antidepressants, antiepileptic drugs, non-
steroidal anti-inflammatory drugs (NSAIDs), opioids, and parac-
etamol as priority areas) in order to review the evidence under
a programme grant for children’s pain utilising pharmacological
interventions in children and adolescents (Appendix 1).
This review is based on a template for reviews of pharmacothera-
pies used to relieve pain in infants, children and adolescents. The
aim is for all reviews to use the same methods, based on new cri-
teria for what constitutes reliable evidence (Appendix 2) (Moore
2010a; Moore 2012). This review focused on NSAIDs to treat
chronic non-cancer pain.
Description of the condition
This review focused on chronic non-cancer pain experienced by
children and adolescents as a result of any type of chronic disease
that occurs throughout the global paediatric population. Chil-
dren’s level of pain can bemild, moderate, or severe, and painman-
agement is an essential element of patient management during all
care stages of chronic disease.
As the leading cause of morbidity in the world today, chronic dis-
ease (and its associated pain) is a major health concern. Chronic
pain can arise in the paediatric population in a variety of patho-
physiological classifications: nociceptive, neuropathic, idiopathic.
Chronic pain is pain that lasts three months or longer and may
be accompanied by changes in lifestyle, personality, and func-
tional abilities, as well as by signs and symptoms of depression
(Ripamonti 2008).
Whilst diagnostic and perioperative procedures performed to treat
chronic diseases are a known common cause of pain in these pa-
tients, this review did not cover perioperative pain or adverse ef-
fects of treatments such as mucositis.
Description of the intervention
Non-steroidal anti-inflammatory drugs are used to treat pain, re-
duce fever, and for their anti-inflammation properties, and are
commonly used within paediatric pain management (Blanca-
Lopez 2015). The two main types of NSAID are selective and
non-selective, which refers to the ability of the NSAID to inhibit
specific types of COX enzymes (Misurac 2013). Non-steroidal
anti-inflammatory drugs are currently licensed for use in Western
countries, however they are not approved for use in infants under
three months of age (WHO 2012). Non-steroidal anti-inflamma-
tory drugs are also widely used for patent ductus arteriosus closure
in neonates.
Currently available NSAIDs include: aceclofenac, acetylsalicylic
acid, celecoxib, choline magnesium trisalicylates, diclofenac,
etodolac, etoricoxib, fenoprofen, ibuprofen, indomethacin, ke-
toprofen, ketorolac, mefenamic acid, meloxicam, nabume-
tone, naproxen, parecoxib, phenylbutazone, piroxicam, sulindac,
tenoxicam, and tiaprofenic acid (BNF 2016).
Non-steroidal anti-inflammatory drugs are used in a variety of
doses and are commonly prescribed to childrenwith pain as an oral
tablet or liquid formulation.The recommendeddose for ibuprofen
(for example) is 5 to 10 mg/kg every six to eight hours, with a
maximum daily dose of 1200 mg. Additionally, the maximum
daily dose recommended for naproxen is 1000 mg per day (WHO
2012). The recommendation for paediatric patients is to use the
lowest dose, for the shortest duration possible to control symptoms
(NICE 2015); hence, NSAIDs are also used in conjunction with
paracetamol to reduce the amount of NSAID administered to
children (WHO 2012).
The two primary adverse effects of NSAIDs are renal impair-
ment and gastrointestinal issues (NICE 2015). Common side ef-
fects in children include diarrhoea, headache, nausea, constipa-
tion, rash, dizziness, flatulence, abdominal pain, and dyspepsia
(WHO 2012). Other adverse effects include hepatic function im-
pairment, contraindications with allergic disorders (hypersensitiv-
ity to aspirin, asthma, angioedema, urticaria, rhinitis), cardiac im-
pairment, Reye’s syndrome, antiplatelet effects, coagulation de-
fects, and dangerous environmental harms (particularly seen in di-
clofenac). The long-term safety of the use of NSAIDs in children
is unclear (Blanca-Lopez 2015). However, some safety assessments
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of ibuprofen in children have been compared with paracetamol
and not found a significant increased risk for serious adverse events
or main causes of hospitalisation (acute gastrointestinal bleeding,
acute renal failure, anaphylaxis, or Reye’s syndrome) (Lesko 1995;
Lesko 1997; Lesko 1999).
How the intervention might work
One current hypothesis is that damage to the peripheral nerves
is followed by an inflammatory reaction that relates to increased
production of prostaglandins, amplifying sodium currents and cal-
cium influx in peripheral nociceptive neurons, and enhancing neu-
rotransmitter release in the central nervous system and depolari-
sation of second-order nociceptive neurons (Vo 2009). Preclinical
data suggest an immune pathogenesis of neuropathic pain, but
clinical evidence of a central role of the immune system is less clear
(Calvo 2012). Non-steroidal anti-inflammatory drugs inhibit the
production of prostaglandins, and thus could lessen the periph-
eral and central sensory hypersensitivity that occurs with nerve
injury-associated inflammation. Non-steroidal anti-inflammatory
drugs have been shown to reduce sensory hypersensitivity in ani-
mal models (Hasnie 2007; Kawakami 2002).
Why it is important to do this review
The paediatric population is at risk of inadequate management
of pain (AMA 2013). Some conditions that would be aggressively
treated in adult patients are being managed with insufficient anal-
gesia in younger populations (AMA 2013). Although there have
been repeated calls for best evidence to treat children’s pain, such
as Eccleston 2003, there are no easily available summaries of the
most effective paediatric pain relief.
This review formed part of a Programme Grant addressing the
unmet needs of people with chronic pain, commissioned by the
National Institute for Health Research (NIHR) in the UK. This
topic was identified in June 2015 during consultation with experts
in paediatric pain. Please see Appendix 1 for full details of the
meeting. The standards used to assess evidence in chronic pain
trials have changed substantially in recent years, with particular
attention being paid to trial duration, withdrawals, and statisti-
cal imputation following withdrawal, all of which can substan-
tially alter estimates of efficacy. The most important change was
to encourage a move from using average pain scores, or average
change in pain scores, to the number of people who have a large
decrease in pain (by at least 50%). Pain intensity reduction of 50%
or more has been shown to correlate with improvements in co-
morbid symptoms, function, and quality of life (Moore 2011a).
These standards are set out in the reference guide for pain studies
(AUREF 2012).
O B J E C T I V E S
To assess the analgesic efficacy and adverse events of NSAIDs used
to treat chronic non-cancer pain in children and adolescents aged
between birth and 17 years, in any setting.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We only included randomised controlled trials, with or without
blinding, and participant- or observer-reported outcomes.
Full journal publication was required, with the exception of online
clinical trial results, summaries of otherwise unpublished clinical
trials, and abstracts with sufficient data for analysis. We included
studies published in any language. We excluded abstracts (usually
meeting reports) or unpublished data, non-randomised studies,
studies of experimental pain, case reports, and clinical observa-
tions.
Types of participants
We included studies of infants, children, and adolescents, aged
from birth to 17 years old, with chronic or recurrent pain (lasting
for three months or longer), arising from genetic conditions, neu-
ropathy, or other conditions. These included but were not limited
to chronic musculoskeletal pain and chronic abdominal pain.
We excluded studies of perioperative pain, acute pain, cancer pain,
and pain associated with primary disease or its treatment. We ex-
cluded headache and migraine (particularly prophylaxis), as these
are addressed in separate Cochrane reviews.
We included studies of participants with more than one type of
chronic pain, and then analysed results according to the primary
condition.
Types of interventions
We included studies reporting interventions prescribing NSAIDs
for the relief of chronic pain, by any route, in any dose, with
comparison to placebo or any active comparator.
Types of outcome measures
In order to be eligible for inclusion in this review, studies had
to report pain assessment, as well as meeting the other selection
criteria.
We included trialsmeasuring pain intensity and pain relief assessed
using validated tools such as numerical rating scale (NRS), visual
analogue scale (VAS), Faces Pain Scale - Revised (FPS-R), Colour
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Analogue Scale (CAS), or any other validated numerical rating
scale.
We were particularly interested in Pediatric Initiative onMethods,
Measurement, and Pain Assessment in Clinical Trials (PedIMM-
PACT) definitions for moderate and substantial benefit in chronic
pain studies (PedIMMPACT 2008). These are defined as: at least
30% pain relief over baseline (moderate); at least 50% pain relief
over baseline (substantial); much or very much improved on Pa-
tient Global Impression of Change (PGIC) scale (moderate); very
much improved on PGIC (substantial).
These outcomes differ from those used in most earlier reviews,
concentrating as they do on dichotomous outcomes where pain
responses do not follow a normal (Gaussian) distribution. People
with chronic pain desire high levels of pain relief, ideally more
than 50% pain intensity reduction, and ideally having no worse
than mild pain (Moore 2013a; O’Brien 2010).
We also recorded any reported adverse events. We reported the
timing of outcome assessments.
Primary outcomes
1. Participant-reported pain relief of 30% or greater
2. Participant-reported pain relief of 50% or greater
3. PGIC much or very much improved
In the absence of self reported pain, we considered the use of
’other-reported’ pain, typically by an observer such as a parent,
carer, or healthcare professional (Stinson 2006; von Baeyer 2007).
Secondary outcomes
We identified the following with reference to the PedIMMPACT
recommendations, which suggest core outcome domains andmea-
sures for consideration in paediatric acute and chronic/recurrent
pain clinical trials (PedIMMPACT 2008).
1. Carer Global Impression of Change
2. Requirement for rescue analgesia
3. Sleep duration and quality
4. Acceptability of treatment
5. Physical functioning as defined by validated scales
6. Quality of life as defined by validated scales
7. Any adverse events
8. Withdrawals due to adverse events
9. Any serious adverse event. Serious adverse events typically
include any untoward medical occurrence or effect that at any
dose results in death, is life-threatening, requires hospitalisation
or prolongation of existing hospitalisation, results in persistent or
significant disability or incapacity, is a congenital anomaly or
birth defect, is an ’important medical event’ that may jeopardise
the participant, or may require an intervention to prevent one of
the above characteristics or consequences.
Search methods for identification of studies
We developed the search strategy based on previous strategies used
within the Cochrane Pain, Palliative and Supportive Care Review
Group and carried out the searches.
Electronic searches
We searched the following databases:
• Cochrane Central Register of Controlled Trials
(CENTRAL) (via the Cochrane Register of Studies Online),
searched 6 September 2016;
• MEDLINE (via Ovid) 1946 to September week 2 2016,
searched 6 September 2016;
• Embase (via Ovid) 1974 to 2016 week 38, searched 6
September 2016.
We used medical subject headings (MeSH) or equivalent and text
word terms. We restricted our search to randomised controlled
trials and clinical trials. Therewere no language or date restrictions.
The focus of the keywords in our search terms was on chronic pain
and NSAIDs. We tailored searches to individual databases. The
search strategies for MEDLINE, Embase, and CENTRAL are in
Appendix 3, Appendix 4, and Appendix 5, respectively.
Searching other resources
We searched ClinicalTrials.gov (www.clinicaltrials.gov) and the
World Health Organization International Clinical Trials Reg-
istry Platform (WHO ICTRP) (apps.who.int/trialsearch/) on 6
September for ongoing trials. In addition, we checked reference
lists of reviews and retrieved articles for additional studies, and
performed citation searches on key articles. We planned to con-
tact experts in the field for unpublished and ongoing trials. We
planned to contact study authors for additional information where
necessary.
Data collection and analysis
We performed separate analyses according to particular chronic
pain conditions. We combined different chronic pain conditions
in analyses for exploratory purposes only.
Selection of studies
Two review authors independently determined study eligibility
by reading the abstract of each study identified by the search.
Review authors independently eliminated studies that clearly did
not satisfy the inclusion criteria, and obtained full copies of the
remaining studies. Two review authors independently read these
studies to select those that met the inclusion criteria, a third review
author adjudicating in the event of disagreement. We did not
anonymise the studies in anyway before assessment.We included a
PRISMAflow chart in Figure 1 to illustrate the results of the search
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and the process of screening and selecting studies for inclusion
in the review (Moher 2009), as recommended in section 11.2.1
of the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011). We included studies in the review irrespective of
whether measured outcome data were reported in a ‘usable’ way.
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Figure 1. Study flow diagram.
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Data extraction and management
We obtained full copies of the studies, and two review authors in-
dependently carried out data extraction. Where this information
was available, we extracted data on pain condition, number of par-
ticipants treated, drug and dosing regimen, study design (placebo
or active control), study duration and follow-up, analgesic out-
come measures and results, withdrawals, and adverse events (par-
ticipants experiencing any adverse event or serious adverse event).
We collated multiple reports of the same study, so that each study
rather than each report was the unit of interest in the review. We
collected characteristics of the included studies in sufficient detail
to populate a ‘Characteristics of included studies’ table.
We used a template data extraction form and checked for agree-
ment before entry intoCochrane’s statistical softwareReviewMan-
ager 5 (RevMan 2014).
If a study had more than two intervention arms, we only included
the data from the intervention and control groups that met the
eligibility criteria. If we included multi-arm studies, we planned
to analyse multiple intervention groups in an appropriate way
that avoided arbitrary omission of relevant groups and double-
counting of participants.
Assessment of risk of bias in included studies
Two review authors independently assessed risk of bias for each
study, using the criteria outlined in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011).
We completed a ’Risk of bias’ table for each included study using
the Cochrane ’Risk of bias’ tool in Review Manager 5 (RevMan
2014).
We assessed the following for each study. Any disagreements were
resolved by discussion between review authors or by consulting a
third review author when necessary.
1. Random sequence generation (checking for possible
selection bias). We assessed the method used to generate the
allocation sequence as: low risk of bias (i.e. any truly random
process, e.g. random number table; computer random number
generator); or unclear risk of bias (when the method used to
generate the sequence is not clearly stated). We excluded studies
that used a non-random process and were therefore at high risk
of bias (e.g. odd or even date of birth; hospital or clinic record
number).
2. Allocation concealment (checking for possible selection
bias). The method used to conceal allocation to interventions
prior to assignment determines whether intervention allocation
could have been foreseen in advance of, or during, recruitment,
or changed after assignment. We assessed the methods as: low
risk of bias (e.g. telephone or central randomisation;
consecutively numbered, sealed, opaque envelopes); or unclear
risk of bias (when the method is not clearly stated). We excluded
studies that did not conceal allocation and were therefore at a
high risk of bias (e.g. open list).
3. Blinding of participants and personnel (checking for
possible performance bias). We assessed any methods used to
blind the participants and personnel from knowledge of which
intervention a participant received. We assessed the methods as:
low risk of bias (study states that the participants and personnel
involved were blinded to treatment groups); unclear risk of bias
(study does not state whether or not participants and personnel
were blinded to treatment groups); or high risk of bias
(participants or personnel were not blinded) (as stated in Types
of studies, we included trials with or without blinding, and
participant- or observer-reported outcomes).
4. Blinding of outcome assessment (checking for possible
detection bias). We assessed any methods used to blind the
outcome assessors from knowledge of which intervention a
participant received. We assessed the methods as: low risk of bias
(e.g. study states that it was single-blinded and describes the
method used to achieve blinding of the outcome assessor);
unclear risk of bias (study states that outcome assessors were
blinded but does not provide an adequate description of how this
was achieved); or high risk of bias (outcome assessors were not
blinded) (as stated in Types of studies, we included trials with or
without blinding, and participant- or observer-reported
outcomes).
5. Incomplete outcome data (checking for possible attrition
bias due to the amount, nature, and handling of incomplete
outcome data). We assessed the methods used to deal with
incomplete data as: low risk of bias (i.e. less than 10% of
participants did not complete the study or used ’baseline
observation carried forward’ (BOCF) analysis, or both); unclear
risk of bias (used ’last observation carried forward’ (LOCF)
analysis); or high risk of bias (used ’completer’ analysis).
6. Selective reporting (checking for possible reporting bias).
We assessed the methods used to report the outcomes of the
study as: low risk of bias (if all planned outcomes in the protocol
or methods were reported in the results); unclear risk of bias (if
there was not a clear distinction between planned outcomes and
reported outcomes); or high risk of bias (if some planned
outcomes from the protocol or methods were clearly not
reported in the results).
7. Size of study (checking for possible biases confounded by
small size) (Dechartres 2013; Dechartres 2014; McQuay 1998;
Nüesch 2010; Thorlund 2011). We assessed studies as being at
low risk of bias (200 participants or more per treatment arm);
unclear risk of bias (50 to 199 participants per treatment arm); or
high risk of bias (fewer than 50 participants per treatment arm).
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8. Other bias, such as multiple publications, financial
declarations, participants with conflicts of interest. We assessed
studies for any additional sources of bias as low, unclear, or high
risk of bias, and provided rationale.
Measures of treatment effect
Where dichotomous data were available, we calculated a risk ra-
tio (RR) with 95% confidence interval (CI) and meta-analysed
the data as appropriate. We calculated numbers needed to treat
for an additional beneficial outcome (NNTBs) where appropri-
ate (McQuay 1998); for unwanted effects the NNTB becomes
the number needed to treat for an additional harmful outcome
(NNTH) and is calculated in the same manner. Where continu-
ous data were reported, we used appropriate methods to combine
these data in the meta-analysis.
Unit of analysis issues
We accepted randomisation to the individual participant only.We
split the control treatment arm between active treatment arms in
a single study if the active treatment arms were not combined for
analysis. We only accepted studies with minimum 10 participants
per treatment arm.
Dealing with missing data
We used intention-to-treat analysis where the intention-to-treat
population consisted of participants who were randomised, took
at least one dose of the assigned study medication, and provided
at least one post baseline assessment. We assigned missing partic-
ipants zero improvement wherever possible.
Assessment of heterogeneity
We identified and measured heterogeneity as recommended in
Chapter 9 of the Cochrane Handbook for Systematic Reviews of In-
terventions (Higgins 2011). We dealt with clinical heterogeneity
by combining studies that examined similar conditions. We un-
dertook and presented a meta-analysis only if we judged partici-
pants, interventions, comparisons, and outcomes to be sufficiently
similar to ensure a clinically meaningful answer. We assessed sta-
tistical heterogeneity visually and by using the I² statistic (L’Abbé
1987). When I² was greater than 50%, we considered the possible
reasons.
Assessment of reporting biases
We assessed the risk of reporting bias, as recommended in chapter
8 of the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011).
The aim of this reviewwas to use dichotomous outcomes of known
utility and of value to patients (Hoffman 2010; Moore 2010b;
Moore 2010c; Moore 2010d; Moore 2013a). The review did not
depend on what the authors of the original studies chose to report
or not, though clearly difficulties would arise in studies failing to
report any dichotomous results.We extracted and used continuous
data, which probably reflect efficacy and utility poorly, and may
be useful for illustrative purposes only.
We assessed publication bias using amethod designed to detect the
amount of unpublished data with a null effect required to make
any result clinically irrelevant (usually taken to mean a number
needed to treat (NNT) of 10 or higher) (Moore 2008).
Data synthesis
We planned to use a fixed-effect model for meta-analysis. We used
a random-effects model for meta-analysis if there was significant
clinical heterogeneity andwe considered it appropriate to combine
studies. We conducted our analysis using the primary outcomes of
pain and adverse events, and planned to calculate the NNTHs for
adverse events. We used the Cochrane software program Review
Manager 5 (RevMan 2014).
Quality of the evidence
To analyse data, two review authors independently rated the qual-
ity of each outcome. We used the GRADE approach to assess the
quality of the body of evidence related to each of the key out-
comes, and reported our judgement in a ’Summary of findings’
table per Chapter 12 of the Cochrane Handbook (Appendix 6)
(Higgins 2011).
In addition, there may be circumstances where the overall rating
for a particular outcome would need to be adjusted per GRADE
guidelines (Guyatt 2013a). For example, if there are so few data
that the results are highly susceptible to the randomplay of chance,
or if studies used LOCF imputation in circumstances where there
were substantial differences in adverse event withdrawals, one
would have no confidence in the result, and would need to down-
grade the quality of the evidence by three levels, to very low qual-
ity. In circumstances where no data were reported for an outcome,
we would report the level of evidence as ’no evidence to support
or refute’ (Guyatt 2013b).
’Summary of findings’ table
We included two ’Summary of findings’ tables as set out in the
Cochrane Pain, Palliative and Supportive Care Review Group’s
author guide (AUREF 2012), and recommended in section 4.6.6
of the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011). We justified and documented all assessments of
the quality of the body of evidence.
In an attempt to interpret reliability of the findings for this system-
atic review, we assessed the summarised data using the GRADE
guidelines (Appendix 6) to rate the quality of the body of evidence
of each of the key outcomes listed in Types of outcome measures
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per Chapter 12 of the Cochrane Handbook (Guyatt 2011; Higgins
2011), as appropriate. Utilising the explicit criteria against study
design, risk of bias, imprecision, inconsistency, indirectness, and
magnitude of effect, we summarised the evidence in an informa-
tive, transparent, and succinct ’Summary of findings’ table or ’Ev-
idence profile’ table (Guyatt 2011).
Subgroup analysis and investigation of heterogeneity
We planned to perform subgroup analyses where a minimum
number of data were available (at least 200 participants per treat-
ment arm). We planned to analyse according to age group; type
of drug; geographical location or country; type of control group;
baseline measures; frequency, dose, and duration of drugs; and
nature of drug.
We planned to investigate whether the results of subgroups were
significantly different by inspecting the overlap of confidence in-
tervals and performing the test for subgroup differences available
in Review Manager 5.
Sensitivity analysis
We did not plan to carry out any sensitivity analysis because the
evidence base is known to be too small to allow reliable analysis; we
did not plan to pool results from chronic pain of different origins
in the primary analyses. We examined details of dose escalation
schedules in the unlikely circumstance that this could provide
some basis for a sensitivity analysis.
R E S U L T S
Description of studies
Results of the search
A PRISMA flow diagram of the search results is shown in Figure
1.
The three main databases searches revealed 4791 titles, of which
1404 duplicates were removed. Our searches of ClinicalTrials.gov
and the WHO ICTRP yielded no additional eligible studies.
We screened the remaining 3387 titles and abstracts for eligibility,
removing 3373 as ineligible studies.
We read the full-text reports of the remaining 14 studies.We found
seven to be ineligible. We identified no ongoing studies.
Seven studies fulfilled the eligibility criteria, and provided data.
Due to these studies comparing different types of NSAIDs, none
could be entered into a quantitative meta-analysis.
Included studies
We included seven studies in this review. See Characteristics of
included studies.
Bhettay 1978 investigated 30 participants (2 to 16 years of age) in
a multicentre, randomised, double-blind, active comparator-con-
trolled, cross-over study. Participants had a diagnosis of juvenile
chronic arthritis. The report did not state gender ratios. Partici-
pants were split into two groups, and the administration of drugs
(ketoprofen versus indomethacin) was randomised. Participants
received doses depending on weight. Participants < 20 kg received
oral capsules of ketoprofen 25 mg capsule twice daily; participants
> 20 kg received ketoprofen capsules x 2 = 50 mg twice daily, or
participants < 20 kg received indomethacin 25 mg capsule twice
daily; participants > 20 kg received indomethacin capsules x 2 =
50 mg twice daily, for five weeks. People were excluded if known
history of contraindications to study drugs; receiving gold, d-peni-
cillamine, or corticosteroids; or in a state of remission.
Brewer 1982 investigated 99 participants in a multicentre, ran-
domised, double-blind, active comparator-controlled, parallel-
group study. Participants had a diagnosis of functional abdomi-
nal pain, functional dyspepsia, and irritable bowel syndrome ac-
cording to the Rome II criteria (see Brewer 1982). Participants
were 8 to 17 years old; 73% were female. Participants received
oral capsules of aspirin 1500 mg/m2 /d increased to 3000 mg/m
2/d, maximum 5450 mg/d (n = 49), or fenoprofen 900 mg/m2/d
increased to 1800 mg/m2/d, maximum 3200 mg/d (n = 50), for
12 weeks. The study did not report exclusion criteria.
Foeldvari 2009 investigated 242 participants in a multicentre,
randomised, double-blind, active comparator-controlled, parallel-
group study. Participants had a diagnosis of pauciarticular or pol-
yarticular course juvenile rheumatoid arthritis (JRA),with orwith-
out systemic onset, according to American College of Rheumatol-
ogy (ACR) criteria; > 1 swollen joint with limited motion; parent
global assessment≥ 10mm (visual analogue scale (VAS) 100mm).
Participants were 2 to 16 years old; 70% were female. Participants
received oral capsules of celecoxib 50 mg/5 mL oral suspension
(target dose approximately 3 mg/kg twice daily) (n = 77); cele-
coxib 100 mg/5 mL oral suspension (target dose approximately
6 mg/kg twice daily) (n = 82); or naproxen 125 mg/5 mL oral
suspension (target dose approximately 7.5 mg/kg twice daily) (n =
83), for 12 weeks. People were excluded if they had active systemic
manifestations; oral corticosteroid doses ≤ 0.2 mg/kg/day or 10
mg prednisone or methotrexate < 1 mg/kg/week.
Giannini 1990 investigated 92 participants in a multicentre, ran-
domised, double-blind, active comparator-controlled, parallel-
group study. Participants had a diagnosis of any of the three types
of JRA (systemic, pauciarticular, or polyarticular); minimum one
joint with active arthritis; free of other chronic illness. Participants
were 2 to 15 years old; 83% were female. Participants received
ibuprofen suspension (concentration 100 mg/5 mL) + placebo as-
pirin (n = 45); or aspirin 200 mg tablet (participant weight 10 to
30 kg) or 300 mg capsules (participant weight > 30 kg) + placebo
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ibuprofen (n = 47). At week 2, physicians had the option to in-
crease dose to 40 mg/kg/day ibuprofen or 80 mg/kg/day aspirin,
provided there were no significant side effects. Exclusion criteria
included those who did not complete the 72-hour washout pe-
riod of all other NSAIDs; previous ibuprofen or slower-acting an-
tirheumatic drugs at least 3 months before entry; immunosup-
pressive therapy at least 6 months before entry; acute illnesses that
might interfere with or compromise the absorption of the medi-
cation.
Moran 1979 investigated 23 participants in a multicentre, ran-
domised, double-blind, active comparator-controlled, cross-over
study. Participants had a diagnosis of seronegative juvenile pol-
yarthritis with disease sufficiently active to be considered in need
of an anti-inflammatory analgesic agent. Participants were 5 to
16 years old; gender ratios were not stated. Participants received
naproxen 10 mg/kg/24 hours given as a suspension in 2 divided
doses; or aspirin soluble 80 mg/kg/day, divided into 4 doses, for 2
x 4 weeks. The study did not report exclusion criteria.
Reiff 2006 investigated 310 participants in a multicentre, ran-
domised, double-blind, double-dummy, active comparator-con-
trolled, parallel-group study. Participants had a diagnosis of pau-
ciarticular (oligo) or polyarticular course JRA for ≥ 3 months
meeting the ACR criteria for JRA, with a patient assessment of
overall well-being (0 to 100 VAS) of > 90 and at least one swollen
joint. Participants were 2 to 17 years old (2 to 11 years = chil-
dren; 12 to 17 years = adolescents); 73% were female. Participants
(N = 209) received: (children) lower-dose rofecoxib 0.3 mg/kg/
day maximum 12.5 mg/day, or higher-dose rofecoxib 0.6 mg/kg/
day maximum 25 mg/day; (adolescents) rofecoxib 12.5 or 25 mg
daily; or (N = 101): (children) naproxen 15 mg/kg/day 5 mg oral
suspension; (adolescents) 15 mg/kg/day maximum 1000 mg/day,
for 12 weeks. People were excluded if they had active systemic JRA
symptoms within 3 months of randomisation or if they were not
within the 5th to 95th percentile of weight for height; hypersensi-
tivity to aspirin and/or an NSAID; unstable antirheumatic medi-
cation regimens; requiring alkylating agents, anticonvulsants, war-
farin, or rifampicin; female participants who had reached menar-
che were required to be in a non-gravid state as determined by
measurement of serum beta-human chorionic gonadotropin.
Ruperto 2005 investigated 90 participants in a multicentre, ran-
domised, double-blind, active comparator-controlled, parallel-
group study. Participants had a diagnosis of juvenile idiopathic
arthritis (JIA) (Durban criteria); NSAID therapy is required; have
at least two joints with active arthritis plus abnormal results in at
least two of any of the five remaining JIA core set criteria. Partici-
pants were 2 to 16 years old; 65% were male. Participants received
oral capsules of meloxicam 0.125 mg/kg, plus a placebo naproxen
tablet, one dose per day (n = 73); or meloxicam 0.25 mg/kg, plus
a placebo naproxen tablet, one dose per day (n = 74); or naproxen
5 mg/kg, twice per day (n = 78); for 48 weeks. People were ex-
cluded if they had current systemic manifestations; abnormal lab-
oratory results unrelated to JIA; pregnancy, breastfeeding; bleed-
ing disorders; peptic ulcer in past six months; hypersensitivity to
NSAIDs; other rheumatic conditions; other medications related
to rheumatic conditions; taking other NSAIDs.
Excluded studies
See Characteristics of excluded studies.
We excluded seven studies in this review. Five investigated pain in
adults, and two were not randomised controlled trials.
Risk of bias in included studies
A summary of the ’Risk of bias’ assessment is in Figure 2. Full
details of ’Risk of bias’ assessments are in the Characteristics of
included studies tables.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Random sequence generation
One study adequately described the methods used to randomise
participants (Reiff 2006). We judged this study as at low risk of
selection bias for random sequence generation.
Six studies were stated as randomised but no methods used to
randomise the participants were described (Bhettay 1978; Brewer
1982; Foeldvari 2009; Giannini 1990; Moran 1979; Ruperto
2005). We judged these studies as at unclear risk of selection bias
for random sequence generation.
Allocation concealment
One study adequately described themethods used to conceal treat-
ment group from participants (Reiff 2006). We judged this study
as at low risk of selection bias for allocation concealment.
Six studies did not describe anymethods used to conceal treatment
group from participants (Bhettay 1978; Brewer 1982; Foeldvari
2009; Giannini 1990; Moran 1979; Ruperto 2005). We judged
these studies as at unclear risk of selection bias for allocation con-
cealment.
Blinding
Performance bias
Three studies adequately described the methods used to maintain
blinding in both participants and study personnel fromknowledge
of the treatment groups (Brewer 1982; Reiff 2006; Ruperto 2005).
We judged these studies as at low risk of performance bias.
Three studies were stated as double-blind but the methods used to
maintain blinding in both participants and study personnel from
knowledge of the treatment groups were not adequately described
(Bhettay 1978; Foeldvari 2009; Moran 1979). We judged these
studies as at unclear risk of performance bias.
One study attempted to double-blind, however as one treatment
was liquid and the other was a tablet it seemed possible that
the participants could have known which treatment they received
(Giannini 1990). We judged this study as at high risk of perfor-
mance bias.
Detection bias
None of the studies adequately described the methods used to
conceal and blind the outcome assessors from knowledge of the
treatment groups (Bhettay 1978; Brewer 1982; Foeldvari 2009;
Giannini 1990; Moran 1979; Reiff 2006; Ruperto 2005). We
judged all seven included studies as at unclear risk of detection
bias.
Incomplete outcome data
Four studies adequately accounted for all participants from the re-
cruitment stage, through randomisation until follow-up, includ-
ing counting all withdrawals (Bhettay 1978; Moran 1979; Reiff
2006; Ruperto 2005). We judged these studies as at low risk of
attrition bias.
In three studies, the authors did not report whether there were
significant differences between completers and non-completers (
Brewer 1982; Foeldvari 2009; Giannini 1990). We judged these
studies as at unclear risk of attrition bias.
Selective reporting
Four studies adequately reported on all the planned outcomes as
initially listed in the methods sections (Giannini 1990; Moran
1979; Reiff 2006; Ruperto 2005). We judged these studies as at
low risk of reporting bias.
Two studies did not adequately report in their results all outcomes
that were planned in themethods sections. In Bhettay 1978, many
data such as themeans and standard deviations, or blood sedimen-
tation rate, haemoglobin level, platelet, and white cell count, were
not reported clearly. In Brewer 1982, the authors stated that “all
investigators used an identical protocol and case report forms”.
However, outcomes were not set out clearly in the methods, and
we were unable to locate a protocol. We judged these studies as at
unclear risk of reporting bias.
In one study, Foeldvari 2009, the Pediatric Quality of Life Inven-
tory score outcome data had been planned but were not reported.
We judged this study as at high risk of reporting bias.
Other potential sources of bias
Size
No studies investigated a study population of more than 200 par-
ticipants per treatment arm, therefore we judged none as at low
risk of bias with regard to size.
Three studies investigated study populations between 225 and
310 participants, which resulted in 50 to 200 participants per
treatment arm (Foeldvari 2009; Reiff 2006; Ruperto 2005). We
judged these studies as at unclear risk of bias with regard to size.
Four studies investigated study populations between 23 and 99
participants, which resulted in fewer than 50 participants per treat-
ment arm (Bhettay 1978; Brewer 1982; Giannini 1990; Moran
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1979). We judged these studies as at high risk of bias with regard
to size.
Other
We found no other potential sources of bias. We judged all seven
included studies as at low risk of bias for this domain.
Effects of interventions
See: Summary of findings for the main comparisonMeloxicam
compared with naproxen for chronic non-cancer pain; Summary
of findings 2Celecoxib compared with naproxen for chronic non-
cancer pain; Summary of findings 3 Rofecoxib compared with
naproxen for chronic non-cancer pain
Results and outcomes of the individual studies are in Appendix 7
(efficacy), and Appendix 8 (adverse events and withdrawals).
Of the seven included studies, no two studies investigated the same
type of NSAID compared with another type, therefore none could
be entered into a quantitative meta-analysis; see table below. The
qualitative analysis of results follows.
Table 1: Types of drug interventions and conditions of
included studies
Study Interventions Condition
Bhettay 1978 ketoprofen vs indomethacin juvenile chronic arthritis
Brewer 1982 aspirin vs fenoprofen juvenile rheumatoid arthritis
Foeldvari 2009 celecoxib vs naproxen juvenile rheumatoid arthritis
Giannini 1990 Ibuprofen vs aspirin juvenile rheumatoid arthritis
Moran 1979 naproxen vs aspirin juvenile chronic polyarthritis
Reiff 2006 naproxen vs rofecoxib juvenile rheumatoid arthritis
Ruperto 2005 meloxicam vs naproxen juvenile idiopathic arthritis
Comparison 1: NSAIDs versus an active comparator
Primary outcomes
Participant-reported pain relief of 30% or greater
Three studies reported participant-reported pain relief of 30% or
greater.
Analysis 1.1, displayed in a forest plot for illustrative purposes
only (Figure 3), shows the difference between low-dose meloxi-
cam (0.125 mg/kg) and high-dose meloxicam (0.25 mg/kg) ver-
sus naproxen (10 mg/kg) is not statistically significant (P > 0.05)
(low-quality evidence) (Ruperto 2005).
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Figure 3. Forest plot of comparison: 1 Meloxicam versus naproxen, outcome: 1.1 Participant-reported pain
relief of 30% or greater.
Analysis 2.1, displayed in a forest plot for illustrative purposes only
(Figure 4), shows the difference between low-dose celecoxib (3mg/
kg) and high-dose celecoxib (6 mg/kg) versus naproxen (10 mg/
kg) is not statistically significant (P > 0.05) (low-quality evidence)
(Foeldvari 2009).
Figure 4. Forest plot of comparison: 2 Celecoxib versus naproxen, outcome: 2.1 Participant-reported pain
relief of 30% or greater.
Analysis 3.1, displayed in a forest plot for illustrative purposes
only (Figure 5), shows the difference between low-dose rofecoxib
(0.3 mg/kg, maximum 12.5 mg/kg) and high-dose rofecoxib (0.6
mg/kg, maximum 25.0 mg/kg) versus naproxen (15 mg/kg) is
not statistically significant (P > 0.05) (low-quality evidence) (Reiff
2006).
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Figure 5. Forest plot of comparison: 3 Rofecoxib versus naproxen, outcome: 3.1 Participant-reported pain
relief of 30% or greater.
We consider the available data for this outcome to be low-quality
evidence, downgraded once for risk of bias and once for impreci-
sion. See Summary of findings for themain comparison; Summary
of findings 2; Summary of findings 3.
The remaining four studies did not report participant-reported
pain relief of 30% or greater (very low-quality evidence) (Bhettay
1978; Brewer 1982; Giannini 1990; Moran 1979).
We consider the overall quality of the evidence for this outcome
to be very low, due to a lack of data from the majority of the
included studies; there is no evidence to support or refute the use
of NSAIDs.
Participant-reported pain relief of 50% or greater
One study reported participant-reported pain relief of 50% or
greater.
Analysis 1.2, displayed in a forest plot for illustrative purposes
only (Figure 6), shows the difference between low-dose meloxi-
cam (0.125 mg/kg) and high-dose meloxicam (0.25 mg/kg) is not
statistically significant (P > 0.05) (low-quality evidence) (Ruperto
2005).
Figure 6. Forest plot of comparison: 1 Meloxicam versus naproxen, outcome: 1.2 Participant-reported pain
relief of 50% or greater.
We consider the available data for this outcome to be low-quality
evidence, downgraded once for risk of bias and once for impreci-
sion.
The remaining six studies did not report participant-reported pain
relief of 50% or greater (very low-quality evidence) (Bhettay 1978;
Brewer 1982; Foeldvari 2009; Giannini 1990; Moran 1979; Reiff
2006).
We consider the overall quality of the evidence for this outcome
to be very low, due to a lack of data from the majority of the
included studies; there is no evidence to support or refute the use
of NSAIDs.
Patient Global Impression of Change much or very much
improved
One study reported PGIC.
Giannini 1990 reported very much improved for ibuprofen 22/
26 participants (85%) and for aspirin 18/20 participants (90%)
(low-quality evidence).
We consider the available data for this outcome to be low-quality
evidence, downgraded once for risk of bias and once for impreci-
sion.
The remaining six studies did not report PGIC (very low-quality
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evidence) (Bhettay 1978; Brewer 1982; Foeldvari 2009; Moran
1979; Reiff 2006; Ruperto 2005).
We consider the overall quality of the evidence for this outcome
to be very low, due to a lack of data from the majority of the
included studies; there is no evidence to support or refute the use
of NSAIDs.
Secondary outcomes
Carer Global Impression of Change
Four studies reported Carer Global Impression of Change in pain
scores.
Brewer 1982 reported parent global assessment of participant
response (satisfactory) to therapy: fenoprofen 69% and aspirin
61.5%. Foeldvari 2009 reported parent global assessment of overall
well-being (100-millimetre VAS), least squares mean change from
baseline (standard error): celecoxib 3 mg/kg: -17.96 (2.42); cele-
coxib 6 mg/kg: -20.45 (2.34); naproxen 7.5 mg/kg: -18.25 (2.33).
Giannini 1990 reported Carer Global Impression of Change:
ibuprofen: 33/42 (79%) and aspirin: 29/35 (83%). Ruperto 2005
reported Carer global impression of disease activity change (VAS 0
to 100) ± (standard deviation), at three months: low-dose meloxi-
cam: 17.6 ± 20.2; high-dose meloxicam: 21.9 ± 23.6; naproxen:
20.8 ± 22.4, and at 12 months: low-dose meloxicam: 13.4 ± 17.6;
high-dose meloxicam: 17.2 ± 22.5; naproxen: 15.9 ± 21.3 (low-
quality evidence).
We consider the available data for this outcome to be low-quality
evidence, downgraded once for risk of bias and once for impreci-
sion.
The remaining three studies did not report Carer Global Impres-
sion of Change in pain scores (very low-quality evidence) (Bhettay
1978; Moran 1979; Reiff 2006).
We consider the overall quality of the evidence for this outcome to
be very low, due to a lack of data; there is no evidence to support
or refute the use of NSAIDs.
Additional information
These four studies, as well as Reiff 2006, also reported Physician
or Investigator Global Impression of Change. Brewer 1982 re-
ported physician global assessment of participant response: feno-
profen: 62% and aspirin: 63%. Foeldvari 2009 reported physician
global assessment of disease activity (100-millimetre VAS), least
squares mean change from baseline (standard error): celecoxib 3
mg/kg: -21.07 (1.86); celecoxib 6 mg/kg: -23.27 (1.80); naproxen
7.5 mg/kg: -21.88 (1.79). Giannini 1990 reported Investigator
Global Evaluation: ibuprofen: 34/44 (78%) and aspirin: 27/35
(77%). Reiff 2006 reported investigators’ global assessment of dis-
ease activity: mean change from baseline (95% confidence interval
(CI)): low-dose rofecoxib: -12.45 (95% CI -14.95 to -9.94); high-
dose rofecoxib: -13.27 (95% CI -15.88 to -10.65); naproxen: -
12.05 (95% CI -14.60 to -9.50). Reiff 2006 also reported partici-
pant/parent global assessment of pain, mean change from baseline
(95%CI): low-dose rofecoxib: -12.50 (95% CI -15.98 to -9.02);
high-dose rofecoxib: -13.12 (95% CI -16.75 to -9.48); naproxen:
-8.43 (95% CI -11.98 to -4.88). Ruperto 2005 reported physi-
cian global impression of disease activity change (VAS 0 to 100) ±
(standard deviation), at three months: low-dose meloxicam: 19.4
± 20.7; high-dose meloxicam: 20.6 ± 20.3; naproxen: 21.1 ± 19.2,
and at 12 months: low-dose meloxicam: 15.4 ± 20.5; high-dose
meloxicam: 16.8 ± 19.0; naproxen: 14.4 ± 16.7 (no judgement of
quality of evidence).
Requirement for rescue analgesia
No studies reported data on this outcome.
We consider the overall quality of the evidence for this outcome to
be very low, due to a lack of data; there is no evidence to support
or refute the use of NSAIDs.
Sleep duration and quality
No studies reported data on this outcome.
We consider the overall quality of the evidence for this outcome to
be very low, due to a lack of data; there is no evidence to support
or refute the use of NSAIDs.
Acceptability of treatment
One study reported acceptability of treatment.
Moran 1979 reported participants’ medication preference at the
end of the trial. Of the 23 participants who took part in both the
naproxen period and the aspirin period, zero rated naproxenmuch
better; 9 rated naproxen better; 9 rated both drug periods equal;
4 rated aspirin better; and 1 rated aspirin much better (very low-
quality evidence).
We consider the available data for this outcome to be very low-
quality evidence, as the number of events was too small to be
meaningful.
The remaining six included studies did not report acceptability
of treatment (very low-quality evidence) (Bhettay 1978; Brewer
1982; Foeldvari 2009;Giannini 1990; Reiff 2006; Ruperto 2005).
We consider the overall quality of the evidence for this outcome
to be very low due to a lack of data; there is no evidence to support
or refute the use of NSAIDs.
Physical functioning as defined by validated scales
Three studies reported physical functioning.
Foeldvari 2009 reported the parent assessment of physical func-
tioning, Child Health Assessment Questionnaire, disability index
(CHAQ-DI) 0 to 3, least squaresmean change frombaseline (stan-
dard error): celecoxib 3 mg/kg: -0.28 (0.05): celecoxib 6 mg/kg:
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-0.32 (0.05): naproxen 7.5 mg/kg: -0.31 (0.05). Reiff 2006 re-
ported CHAQ-DI: mean change from baseline (95% CI): low-
dose rofecoxib: -0.11 (95% CI -0.18 to -0.05); high-dose rofe-
coxib: -0.15 (95% CI -0.21 to -0.08); naproxen: -0.12 (95% CI -
0.18 to -0.05). Ruperto 2005 reported CHAQ-DI (0 to 3 points)
at threemonths: low-dosemeloxicam: 0.4 ±0.5; high-dosemeloxi-
cam: 0.5 ± 0.6; naproxen: 0.5 ± 0.6, and at 12 months: low-dose
meloxicam: 0.3 ± 0.4; high-dose meloxicam: 0.4 ± 0.6; naproxen:
0.3 ± 0.5 (low-quality evidence).
We consider the available data for this outcome to be low-quality
evidence, downgraded once for risk of bias and once for impreci-
sion.
The remaining four studies did not report physical functioning
(very low-quality evidence) (Bhettay 1978; Brewer 1982;Giannini
1990; Moran 1979).
We consider the overall quality of the evidence for this outcome
to be very low due to a lack of data from the majority of the
included studies; there is no evidence to support or refute the use
of NSAIDs.
Quality of life as defined by validated scales
Two studies reported quality of life.
Foeldvari 2009 reported improved Pediatric Quality of Life In-
ventory scores. Participants in the celecoxib 6 mg/kg twice-daily
or naproxen 7.5 mg/kg twice-daily groups scored higher than
those in the celecoxib 3 mg/kg twice-daily group, but results
were non-significant (data not shown in publication). It is unclear
whether differences are between groups or over time. Reiff 2006
reported participant/parent assessment of overall well-being:mean
change from baseline (95%CI) (proportion of improvement from
baseline): low-dose rofecoxib: -11.57 (95% CI -14.78 to -8.36)
(74.3%); high-dose rofecoxib: -12.08 (95% CI -15.44 to -8.73)
(76%); naproxen: -8.56 (95% CI -11.85 to -5.27) (73%) (low-
quality evidence).
We consider the available data for this outcome to be low-quality
evidence, downgraded once for risk of bias and once for impreci-
sion.
The remaining six studies did not report quality of life (very low-
quality evidence) (Bhettay 1978; Brewer 1982; Giannini 1990;
Moran 1979; Ruperto 2005).
We consider the overall quality of the evidence for this outcome
to be very low due to a lack of data from the majority of the
included studies; there is no evidence to support or refute the use
of NSAIDs.
Any adverse events
Six studies reported adverse events.
Participants reporting an adverse event (one or more per person)
by drug were: aspirin 85/120; fenoprofen 28/49; ibuprofen 40/
45; indomethacin 9/30; ketoprofen 9/30; meloxicam 113/147;
naproxen 102/202; and rofecoxib 43/209 (Bhettay 1978; Brewer
1982; Giannini 1990;Moran 1979; Reiff 2006). In addition there
were unclear data on adverse events from 159 celecoxib partici-
pants and 83 naproxen participants (very low-quality evidence)
(Foeldvari 2009).
We consider the available data for this outcome to be very low-
quality evidence, as the number of events was too small to be
meaningful.
Withdrawals due to adverse events
All seven studies reported withdrawals due to adverse events.
Participants withdrawn due to an adverse event by drug were:
aspirin 16/120; celecoxib 10/159; fenoprofen 0/49; ibuprofen
0/45; indomethacin 0/30; ketoprofen 0/30; meloxicam 10/147;
naproxen 17/285; and rofecoxib 3/209 (very low-quality evidence)
(Bhettay 1978; Brewer 1982; Foeldvari 2009; Giannini 1990;
Moran 1979; Reiff 2006; Ruperto 2005).
We consider the available data for this outcome to be very low-
quality evidence, due to a lack of available data, and the number
of events was too small to be meaningful.
Any serious adverse event
All seven studies reported serious adverse events.
We considered serious adverse events to be hospitalisation or death,
however in many cases this level of detail defining a serious adverse
event was not provided.
Participants experiencing a serious adverse event by drug were:
aspirin 13/120; celecoxib 5/159; fenoprofen 0/79; ketoprofen
0/30; ibuprofen 4/45; indomethacin 0/30; meloxicam 11/147;
naproxen 10/285; and rofecoxib 0/209 (very low-quality evidence)
(Bhettay 1978; Brewer 1982; Foeldvari 2009; Giannini 1990;
Moran 1979; Reiff 2006; Ruperto 2005).
We consider the available data for this outcome to be very low-
quality evidence, due to a lack of available data, and the number
of events was too small to be meaningful.
Comparison 2: NSAIDs versus placebo
None of the included studies addressed our second comparison of
an NSAID versus placebo. We consider this overall comparison to
be very low-quality evidence, due to a lack of data from studies.
There is no evidence to support or refute the use of NSAIDs com-
pared with a placebo to treat chronic non-cancer pain in children
and adolescents.
Mean response rate for any NSAID at any dose
As data were insufficient for pooled analyses comparing one drug
to another, we performed a post hoc analysis using the randomised
cohorts of NSAIDs to calculate the mean response rate for any
NSAID at any dose. For our primary outcome of at least 50%
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pain relief, the mean response rate was 45.5%, and the weighted
mean by size of the treatment group was 47.3%. This means that
nearly 1 in every 2 people will achieve at least 50% pain relief from
treatment with one of these NSAIDs. For our primary outcome
of at least 30% pain relief, the mean response rate was 26.0%,
and the weighted mean by size of the treatment group was 29.1%.
This means that about 1 in every 4 people will achieve at least
30% pain relief from treatment with one of these NSAIDs.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Celecoxib compared with naproxen for chronic non-cancer pain
Patient or population: children and adolescents with chronic non-cancer pain
Settings: 17 paediatric centres worldwide
Intervention: celecoxib
Comparison: naproxen
Outcomes Illustrative comparative risks*
(95% CI)
Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Naproxen Celecoxib
Participant-
reported pain relief of
30% or greater
56/ 83 119/ 159 N/ A 242 part icipants
(1 study)
⊕⊕©©
low
© f or risk of bias
© f or imprecision
Participant-
reported pain relief of
50% or greater
No data No data N/ A N/ A ⊕©©©
very low
No evidence to support or
refute* *
Patient Global Impres-
sion of Change much or
very much improved
No data No data N/ A N/ A ⊕©©©
very low
No evidence to support or
refute* *
Any adverse event No data No data N/ A N/ A ⊕©©©
very low
No evidence to support or
refute* *
Serious adverse event 0/ 83 5/ 159 N/ A 242 part icipants
(1 study)
⊕©©©
very low
Number of events too small
to be meaningful
Withdrawals due to ad-
verse events
3/ 83 10/ 159 N/ A 242 part icipants
(1 study)
⊕©©©
very low
Number of events too small
to be meaningful
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* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; N/A: not applicable
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate; the true ef fect is likely to be close to the est imate of ef fect, but there is a possibility that it is substant ially
dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited; the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate; the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
* * In circumstances where there were no data reported for an outcome, we report the level of evidence as ’very low’ with no evidence to support or refute.
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Rofecoxib compared with naproxen for chronic non-cancer pain
Patient or population: children and adolescents with chronic non-cancer pain
Settings: 41 clinical centres in Australia, Europe, Asia, Central America, South America, USA
Intervention: rofecoxib
Comparison: naproxen
Outcomes Illustrative comparative risks* (95%
CI)
Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Naproxen Rofecoxib
Participant-
reported pain relief of
30% or greater
48/ 87 94/ 187 N/ A 274 part icipants
(1 study)
⊕⊕©©
low
© f or risk of bias
© f or imprecision
Participant-
reported pain relief of
50% or greater
No data No data N/ A N/ A ⊕©©©
very low
No evidence to support or
refute* *
Patient Global Impres-
sion of Change much or
very much improved
No data No data N/ A N/ A ⊕©©©
very low
No evidence to support or
refute* *
Any adverse event 28/ 101 43/ 209 N/ A 274 part icipants
(1 study)
⊕©©©
very low
Number of events too small
to be meaningful
Serious adverse event 0/ 101 0/ 209 N/ A 310 part icipants
(1 study)
⊕©©©
very low
Number of events too small
to be meaningful
Withdrawals due to ad-
verse events
3/ 101 3/ 209 N/ A 310 part icipants
(1 study)
⊕©©©
very low
Number of events too small
to be meaningful
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; N/A: not applicable2
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GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate; the true ef fect is likely to be close to the est imate of ef fect, but there is a possibility that it is substant ially
dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited; the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate; the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
* * In circumstances where there were no data reported for an outcome, we report the level of evidence as ’very low’ with no evidence to support or refute.
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D I S C U S S I O N
Summary of main results
We included seven studies in this review reporting data from 1074
participants (aged 2 to 18 years), comparing various combinations
of the following NSAIDs: aspirin, celecoxib, fenoprofen, ibupro-
fen, indomethacin, ketoprofen, meloxicam, naproxen, and rofe-
coxib. No studies compared the intervention drug with placebo.
No two included studies investigated the same type of NSAID
compared with another type of NSAID. Consequently, no studies
could be entered into a quantitative meta-analysis.
Risk of bias for the included studies varied. For randomisation and
allocation concealment, one study was low risk and six were un-
clear risk. For blinding of participants and personnel, three stud-
ies were low risk and four were unclear to high risk. For blinding
of outcome assessors, all studies were unclear risk. For attrition,
four studies were low risk and three were unclear risk. For selective
reporting, four studies were low risk, two were unclear risk, and
one was high risk. For size, three studies were unclear risk and four
were high risk. For other potential sources of bias, seven studies
were low risk.
There is no evidence from randomised controlled trials to suggest
that NSAIDs are effective in treating chronic non-cancer pain in
children or adolescents, nor do we have evidence to suggest that
one NSAID is more effective than another to treat chronic non-
cancer pain in children or adolescents.
Overall completeness and applicability of
evidence
We identified only a small number of studies (seven), with insuf-
ficient data for analysis, of any combination of NSAIDs. As only
three studies, Foeldvari 2009, Reiff 2006, and Ruperto 2005, ad-
dressed our primary outcome, we compared low doses with high
doses of meloxicam, celecoxib, or rofecoxib versus naproxen to
investigate 30% and 50% pain relief responders, and found no
difference in effect.
As we could undertake no meta-analysis, we are unable to com-
ment on efficacy from the use of NSAIDs to treat chronic non-
cancer pain in children and adolescents. Similarly, we cannot com-
ment on our remaining secondary outcomes: CarerGlobal impres-
sion of Change; requirement for rescue analgesia; sleep duration
and quality; acceptability of treatment; physical functioning; and
quality of life. We found small numbers of (mild) adverse effects
across the different NSAIDs, and small numbers of serious adverse
effects, however none resulted in hospitalisation or death.
All seven studies evaluated participants with musculoskeletal dis-
ease-related pain. We identified no studies in non-arthritis popu-
lations.
The suite of reviews
This review is part of a suite of reviews on pharmacological in-
terventions for chronic pain and cancer-related pain in children
and adolescents (Appendix 1). Taking a broader view on this suite
of reviews, some pharmacotherapies (investigated in our other re-
views) are likely to provide more data than others. The results were
thus as expected considering that randomised controlled trials in
children are known to be limited. The results have the potential
to inform policymaking decisions for funding future clinical trials
into NSAID treatment of child and adolescent pain, therefore any
results (large or small) are important in order to capture a snapshot
of the current evidence for NSAIDs.
Quality of the evidence
Of the seven included studies, only one study clearly described
randomisation methods, and only three studies described double-
blindingmethods, however all studies provided information about
withdrawals, dropouts, and adverse events.
The studies recruited participants with adequate baseline pain, but
not all reported clinically useful outcome measures.
The studies themselves were of moderate quality, however the
number of studies and sample sizes for some comparisons were
somewhat limited, given what is known about study size and esti-
mates of effect for outcomes derived from studies with few partic-
ipants and events (Dechartres 2013; Dechartres 2014; McQuay
1998; Nüesch 2010; Thorlund 2011).
The quality of the evidence (GRADE rating) for NSAIDs versus
an active comparator or a placebo across our primary outcomes is
very low, meaning there is no evidence to support or refute. Across
our secondary outcomes, the quality of the evidence is also very
low, as the numbers of events were too small to be meaningful,
meaning there is no evidence to support or refute. As a result, there
is no evidence to support or refute the use of NSAIDs to treat
chronic non-cancer pain in children and adolescents.
Potential biases in the review process
We carried out extensive searches of major databases using broad
search criteria, and also searched two large clinical trial registries.
We consider it to be unlikely that we have missed relevant studies.
Agreements and disagreements with other
studies or reviews
We were not able to identify any published systematic reviews on
this topic.
A U T H O R S ’ C O N C L U S I O N S
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Implications for practice
General
We identified seven randomised controlled trials, however wewere
unable to analyse these to determine whether to support or refute
the use of NSAIDs to treat chronic non-cancer pain in children
and adolescents.
This is disappointing as children and adolescents have specific
needs for analgesia. Extrapolating from adult data may be possible
but could compromise effectiveness and safety.
Despite the lack of evidence of long-term effectiveness and safety,
clinicians prescribe NSAIDs to children and adolescents when
medically necessary, based on extrapolation from adult guidelines,
when perceived benefits in conjunction with other multi modal-
ities improve a child’s care. Appropriate medical management is
necessary in disease-specific conditions such as for incurable pro-
gressive degenerative conditions of Duchenne muscular dystro-
phy, osteogenesis imperfecta, congenital degenerative spine, and
neurodegenerative conditions such as spasticity/dystonia in mito-
chondrial Leigh’s disease, leukoencephalopathy, and severe cere-
bral palsy.
Despite the lack of evidence, NSAIDs are administered to young
children and adolescents in current practice, and some are licensed
for management of pain in children. Whilst our only current
source is the World Health Organization guideline on the phar-
macological treatment of persisting pain in children with medical
illnesses (WHO 2012), we identified no specific evidence-based
guidelines for the use of NSAIDs in chronic non-cancer pain.
For children and adolescents with chronic non-cancer
pain
The amount and quality of evidence around the use of NSAIDs
for treating chronic non-cancer pain is very low. This means that
at present, treatment is based on clinical experience and advice
from respected authorities. We could make no judgement about
adverse events or withdrawals.
For clinicians
The amount and quality of evidence around the use of NSAIDs
for treating chronic non-cancer pain is very low. This means that
at present, treatment is based on clinical experience and advice
from respected authorities. We could make no judgement about
adverse events or withdrawals.
For policymakers
The amount and quality of evidence around the use of NSAIDs
for treating chronic non-cancer pain is very low. This means that
at present, treatment is based on clinical experience and advice
from respected authorities. We could make no judgement about
adverse events or withdrawals.
For funders
The amount and quality of evidence around the use of NSAIDs
for treating chronic non-cancer pain is very low. This means that
at present, treatment is based on clinical experience and advice
from respected authorities. We could make no judgement about
adverse events or withdrawals.
Implications for research
General
Theheterogenous nature of pain in childrenneeds to be recognised
and presents challenges in designing research studies.
Overall, there appears to be a gap between what is done in practice
and what is investigated in prospective clinical trials for treating
children’s and adolescents’ pain with NSAIDs.
The lack of evidence highlighted in this review implies that there
is a need to fund and support suitable research for the treatment
of chronic non-cancer pain in children and adolescents.
Design
Several methodological issues stand out.
The first is the use of outcomes of value to children with chronic
non-cancer pain. Existing trials tend to be designed more for pur-
poses of registration andmarketing than informing and improving
clinical practice, that is the outcomes are often average pain scores
or statistical differences, and rarely how many individuals achieve
satisfactory pain relief. In the case where pain is initially mild or
moderate, consideration needs to be given to what constitutes a
satisfactory outcome.
The second issue is the time taken to achieve good pain relief. We
have no information about what constitutes a reasonable time to
achieve a satisfactory result. This may best be approached initially
with a Delphi methodology.
The third issue is design. Studies with a cross-over design often
have significant attrition, therefore parallel-group designs may be
preferable.
The fourth issue is size. The studies need to be suitably powered
to ensure adequate data after the effect of attrition due to various
causes.Much larger studies of several hundredparticipants ormore
are needed.
There are some other design issues that might be addressed. Most
important might well be a clear decision concerning the gold-
standard treatment comparator.
An alternative approach may be to design large registry studies.
This could provide an opportunity to foster collaboration among
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paediatric clinicians and researchers, in order to create an evidence
base.
Measurement (endpoints)
Trials need to consider the additional endpoint of ’no worse than
mild pain’ as well as the the standard approaches to pain assess-
ment.
Other
The obvious study design of choice is the prospective randomised
trial, but other pragmatic designs may be worth considering. Stud-
ies could incorporate initial randomisation but a pragmatic de-
sign in order to provide immediately relevant information on ef-
fectiveness and costs. Such designs in pain conditions have been
published (Moore 2010e).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bhettay 1978
Methods Allocation: randomised
Blinding: double-blind
Controlled: placebo
Centre: multicentre
Arm: 2 arms, cross-over design
Participants Inclusion criteria: children with juvenile chronic arthritis
Exclusion criteria: known history of contraindications to study drugs; receiving gold,
d-penicillamine, or corticosteroids; in a state of remission
Baseline characteristics
N = 30
Age: mean not reported, range 2 to 16 years
Gender: male (unstated); female (unstated)
Number randomised: intervention (15); control (15)
Number completed: intervention (15); control (15)
Setting and location: South Africa
Interventions Intervention group (N = 15): indomethacin (2 weeks), cross-over ketoprofen (2 weeks)
Control group (N = 15): ketoprofen (2 weeks), cross-over indomethacin (2 weeks)
Participants < 20 kg: ketoprofen 25 mg capsule twice daily; participants > 20 kg: keto-
profen capsules x 2 = 50 mg twice daily
Participants < 20 kg: indomethacin 25 mg capsule twice daily; participants > 20 kg:
indomethacin capsules x 2 = 50 mg twice daily
Study duration: 5 weeks
Outcomes Primary outcomes
1. Severity of pain: morning stiffness; interference with function; general feeling of
well-being; symptoms interpreted by the participant that were due to treatment;
preference of either drug
2. Articular index 0 to 4: passive movement of a joint; knee score; combined finger-
joint circumference
3. Grip strength
4. Temporomandibular joint
5. Patient Impression of Change (5-point scale)
6. Fever, rash, splenomegaly, or lymphadenopathy
7. Investigator’s impression of change
Secondary outcomes
1. Side effects
2. Amount of rescue analgesia
Notes Sources of funding: Maybaker (SA) (Pty) Ltd provided drug supplies.
Risk of bias
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Bhettay 1978 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: Randomised drug administra-
tion, not participants
Allocation concealment (selection bias) Unclear risk Comment: Insufficient information
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: Insufficient information
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: Insufficient information
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment:All participantswere accounted
for. Lost to follow-up and withdrawals ex-
plained
Selective reporting (reporting bias) Unclear risk Comment:Means and standard deviations
not reported, nor blood sedimentation rate,
haemoglobin level, platelet and white cell
count
Size High risk Comment: Total participants = 30 (< 50
per treatment arm)
Other bias Low risk Comment: No other potential sources of
bias found.
Brewer 1982
Methods Allocation: randomised
Blinding: double-blind
Controlled: active comparator
Centre: multicentre
Arm: 2 arms, parallel groups
Participants Inclusion criteria: children with juvenile rheumatoid arthritis
Exclusion criteria: unstated
Baseline characteristics
N = 99
Age: range unstated; mean age 8.5 years
Gender: male (23); female (76)
Number randomised: fenoprofen (49); aspirin (50)
Number completed: fenoprofen (47); aspirin (40)
Setting and location: multicentre, location unstated
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Brewer 1982 (Continued)
Interventions Intervention group (N = 49): aspirin 1500 mg/m2/day increased to 3000 mg/m2/day,
maximum 5450 mg/day
Control group (N = 50): fenoprofen 900 mg/m2/day increased to 1800 mg/m2/day,
maximum 3200 mg/day
Study duration: 12 weeks
Outcomes Primary outcomes
1. Unstated
Secondary outcomes
1. Adverse reactions
Notes Sources of funding: unstated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “99 patients were randomized into
the study”
Comment: No information regarding
method of randomisation
Allocation concealment (selection bias) Unclear risk Quote: Insufficient information
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “capsules containing either feno-
profen or ASA were white opaque size #2
for the 0.5 to 0.75m2 groups, and white
opaque size #1 for the 0.76m2 and over
groups. Therefore it was impossible to de-
termine which drug the subjects were re-
ceiving by observing capsule size, colour, or
administration regimen”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: Insufficient information
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment:All participantswere accounted
for. Lost to follow-up and withdrawals ex-
plained. However, authors do not report
whether there were significant differences
between completers and non-completers
Selective reporting (reporting bias) Unclear risk Quote: “all investigators used an identical
protocol and case report forms”
Comment: No outcomes were not set out
in the methods. Unable to locate protocol
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Brewer 1982 (Continued)
Size High risk Comment: Total participants = 99 (< 50
per treatment arm)
Other bias Low risk Comment: No other potential sources of
bias found.
Foeldvari 2009
Methods Allocation: randomised
Blinding: double-blind
Controlled: active comparator
Centre: multicentre
Arm: 2 arms, parallel groups
Participants Inclusion criteria: children ≥ 9 kg, with pauciarticular of polyarticular course JRA,
with or without systemic onset, according to ACR criteria; > 1 swollen joint with limited
motion; parent global assessment ≥ 10 mm (100-millimetre VAS)
Exclusion criteria: active systemic manifestations; oral corticosteroid doses ≤ 0.2 mg/
kg/day or 10 mg prednisone or methotrexate < 1 mg/kg/week
Baseline characteristics
N = 242
Age: 2 to 16 years
Gender: male (71); female (171)
Number randomised: intervention A (77); intervention B (82); control (83)
Number completed: intervention A (67); intervention B (71); control (74)
Setting and location: 17 centres worldwide
Interventions Intervention group (N = 77): celecoxib 50 mg/5 mL oral suspension (target dose
approximately 3 mg/kg twice daily)
Intervention group (N = 82): celecoxib 100 mg/5 mL oral suspension (target dose
approximately 6 mg/kg twice daily)
Control group (N = 83): naproxen 125 mg/5 mL oral suspension (target dose approx-
imately 7.5 mg/kg twice daily)
Study duration: 12 weeks
Outcomes Primary outcomes
1. Time-weighted average proportion of patients achieving ACR Pediatric 30 (at
least 30% improvement in any 3 of 6 variables)
i) Investigators’ global assessment of disease activity (100-millimetre VAS)
ii) Parent/patient’s global assessment of overall well-being (100-millimetre VAS)
iii) Measure of physical functional ability (CHAQ: 0-to-3-point scale)
iv) Number of joints with active arthritis
v) Number of joints with limited range of motion
vi) Measure of inflammation (ESR)
Secondary outcomes
1. Change from baseline at each visit for the individual Juvenile Rheumatoid
Arthritis score set measures
2. Parent’s assessment of child’s arthritis pain (100-millimetre VAS) as reported on
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Foeldvari 2009 (Continued)
the CHAQ
3. Health-related quality of life (Pediatric Quality of Life Inventory)
Notes Sources of funding: editorial support funded by Pfizer
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “children were randomly assigned
to 1 of 3 treatment groups in a 1:1:1 ratio
... randomized according to the allocation
number provided by an interactive voice
response system”
Allocation concealment (selection bias) Unclear risk Comment: Insufficient information
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: Insufficient information
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: Insufficient information
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment:All participantswere accounted
for. Lost to follow-up and withdrawals ex-
plained. However, authors do not report
whether there were significant differences
between completers and non-completers
Selective reporting (reporting bias) High risk Comment: Secondary outcome data not
reported (e.g. Pediatric Quality of Life In-
ventory)
Size Unclear risk Comment: Total participants = 242 (be-
tween 50 and 200 per treatment arm)
Other bias Low risk Comment: No other potential sources of
bias found.
Giannini 1990
Methods
Participants
38Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Giannini 1990 (Continued)
Interventions Intervention group (N = 45): ibuprofen suspension (concentration 100 mg/5 mL) +
placebo aspirin
Control group (N = 47): aspirin 200 mg tablet (participant weight 10 to 30 kg) or 300
mg capsules (participant weight > 30 kg) + placebo ibuprofen
Week 2: physician’s option to increase dose to 40 mg/kg/day ibuprofen or 80 mg/kg/day
aspirin, provided no significant side effects
Study duration: 12 weeks
Outcomes
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “patients were randomly assigned, in random blocks of
four within each centre, to receive ibuprofen or aspirin”
Allocation concealment (selection bias) Unclear risk Quote: “patients were assigned numbers sequentially, on the
basis of body weight, from blocks of numbers allotted to each
site”
Quote: “Before initiation of this trial, each centre was given a list
of consecutive numbers from Boots Pharamceuticals. Patients
were assigned numbers in the sequence in which they entered
the study”
Quote: “Patients received one of the two active medications plus
a dummy of the alternative agent”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Patients received one of the two active medications plus
a dummy of the alternative agent”
Comment: The study personnel would have known what they
were giving the participants (as one was a liquid and the other
was a tablet)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: Insufficient information
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: All participants were accounted for. Lost to follow-
up and withdrawals explained. However, authors do not report
whether there were significant differences between completers
and non-completers
Selective reporting (reporting bias) Low risk Comment: All planned outcomes from the methods were re-
ported in the results
Size High risk Comment: Total participants = 92 (< 50 per treatment arm)
39Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Giannini 1990 (Continued)
Other bias Low risk Comment: No other potential sources of bias found.
Moran 1979
Methods Allocation: randomised
Blinding: double-blind
Controlled: active comparator
Centre: single
Arm: 2 arms, cross-over design; 4 weeks, followed by cross-over and a further 4 weeks
Participants Inclusion criteria: children suffering from seronegative juvenile polyarthritis; disease
sufficiently active to be considered in need of an anti-inflammatory analgesic agent
Exclusion criteria: unstated
Baseline characteristics
N = 23
Age: 5 to 16 years; median 11 to 12 years
Gender: male (unstated); female (unstated)
Number randomised: intervention (23); control (23)
Number completed: intervention (22); control (20)
Setting and location: unstated
Interventions Intervention group (N = 23): naproxen 10 mg/kg/24 hrs given as a suspension in 2
divided doses
Control group (N = 23): aspirin soluble 80 mg/kg/day, divided into 4 doses
Study duration: 2 x 4 weeks
Outcomes Primary outcomes
1. Functional grading
2. Joint involvement
3. Grip strength
4. Walking time over 20 m
5. Functional test
6. Comparison with last visit to physician
7. Laboratory tests (haemoglobin, full blood count, platelets, ESR, liver function
tests, urea, urine analysis, stools for occult blood)
Secondary outcomes
1. Side effects
Notes Sources of funding: unstated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “random allocation for either ...
drug”
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Moran 1979 (Continued)
Allocation concealment (selection bias) Unclear risk Comment: Insufficient information
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “placebo suspension and tablets
were given tomake the study double-blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “placebo suspension and tablets
were given tomake the study double-blind”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment:All participantswere accounted
for. Lost to follow-up and withdrawals ex-
plained
Selective reporting (reporting bias) Low risk Comment: All planned outcomes from the
methods were reported in the results
Size High risk Comment: Total participants = 23 (< 50
per treatment arm)
Other bias Low risk Comment: No other potential sources of
bias found.
Reiff 2006
Methods Allocation: randomised
Blinding: double-blind, double-dummy
Controlled: active comparator
Centre: multicentre
Arm: 2 arms, parallel groups
Participants Inclusion criteria: children with pauci- (oligo) or polyarticular course JRA for ≥ 3
months meeting the ACR criteria for juvenile rheumatoid arthritis. Must have patient
assessment of overall well-being (0-to-100 VAS) of > 90 with at least 1 swollen joint
Exclusion criteria: active systemic JRA symptoms within 3 months of randomisation or
if they were not within the 5th to 95th percentile of weight for height; hypersensitivity to
aspirin and/or an NSAID; unstable antirheumatic medication regimens; requiring alky-
lating agents, anticonvulsants, warfarin, or rifampicin; female patients who had reached
menarche were required to be in a non-gravid state as determined by measurement of
serum beta-human chorionic gonadotropin
Baseline characteristics
N = 310
Age: 2 to 17 years; mean 9.9 years
Gender: male (83); female (227)
Number randomised: intervention A (109); intervention B (100); control (101)
Number completed: intervention A (99); intervention B (95); control (91)
Setting and location: 41 clinical centres in Australia, Europe, Asia, Central America,
South America, USA
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Reiff 2006 (Continued)
Interventions Intervention group (N = 209): (children) low-dose rofecoxib 0.3 mg/kg/day maximum
12.5 mg/day, or high-dose rofecoxib 0.6 mg/kg/day maximum 25 mg/day; (adolescents)
rofecoxib 12.5 or 25 mg daily
Control group (N = 101): (children) naproxen 15 mg/kg/day 5 mg oral suspension;
(adolescents) 15 mg/kg/day maximum 1000 mg/day
Study duration: 12 weeks (+ 52-week open-label extension)
Outcomes Primary outcomes
1. Time-weighted average proportion of patients achieving ACR Pediatric 30 (at
least 30% improvement in any 3 of 6 variables
i) Investigators’ global assessment of disease activity (100-millimetre VAS)
ii) Parent/patient’s global assessment of overall well-being (100-millimetre VAS)
iii) Measure of physical functional ability (CHAQ: 0-to-3-point scale)
iv) Number of joints with active arthritis
v) Number of joints with limited range of motion
vi) Measure of inflammation (ESR)
Secondary outcomes
1. Proportion of patients showing improvement from baseline using (b) above
2. Safety assessments - adverse events
3. Serious adverse events
Notes Sources of funding: unstated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomisa-
tion to treatment groups in equal propor-
tionswas performed using a computer-gen-
erated allocation schedule. Treatment as-
signment was stratified based on joint in-
volvement (pauci- or polyarticular course)
and age group (2-11 years or 12-17 years).
”
Allocation concealment (selection bias) Low risk Quote: “randomisa-
tion to treatment groups in equal propor-
tionswas performed using a computer-gen-
erated allocation schedule. Treatment as-
signment was stratified based on joint in-
volvement (pauci- or polyarticular course)
and age group (2-11 years or 12-17 years).
”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “to maintain blinding to treatment
assignment during the base study, each pa-
tient received 2 coded test products - active
or identical-appearing placebo”
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Reiff 2006 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: Insufficient information
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment:All participantswere accounted
for. Lost to follow-up and withdrawals ex-
plained
Selective reporting (reporting bias) Low risk Comment: All planned outcomes from the
methods section were reported in the re-
sults
Size Unclear risk Comment: Total participants = 310 (be-
tween 50 and 200 per treatment arm)
Other bias Low risk Comment: No other potential sources of
bias found.
Ruperto 2005
Methods Allocation: randomised
Blinding: double-blind, double-dummy
Controlled: active comparator
Centre: multicentre
Arm: 3 arms, parallel groups
Participants Inclusion criteria: diagnosis of JIA (Durban criteria); NSAID therapy is required; have
at least 2 joints with active arthritis plus abnormal results in at least 2 of any of the 5
remaining JIA core set criteria
Exclusion criteria: current systemic manifestations; abnormal laboratory results unre-
lated to JIA; pregnancy, breastfeeding; bleeding disorders; peptic ulcer in past 6 months;
hypersensitivity to NSAIDs; other rheumatic conditions; other medications related to
rheumatic conditions; taking other NSAIDs
Baseline characteristics
N = 225
Age: 2 to 16 years
Gender: male (148); female (67)
Number randomised: meloxicam low (73); meloxicam high (74); naproxen (78)
Number completed: meloxicam low (58); meloxicam high (63); naproxen (61)
Setting and location: 34 paediatric rheumatology tertiary care units in Austria, Belgium,
France, Germany, Italy, Russia, and the UK
Interventions Intervention group 1 (N = 73): meloxicam 0.125 mg/kg, 1 dose per day
Intervention group 2 (N = 74): meloxicam 0.25 mg/kg, 1 dose per day
Control group (N = 78): naproxen 5 mg/kg, twice per day
Placebo ’naproxen’ tablets for the meloxicam groups and placebo ’meloxicam’ tablets for
the naproxen group
Study duration: 48 weeks
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Ruperto 2005 (Continued)
Outcomes Primary outcomes
1. At least 30% improvement from baseline (ACR Pediatric 30 criteria)
2. At least 50% improvement from baseline (ACR Pediatric 30 criteria)
3. At least 70% improvement from baseline (ACR Pediatric 30 criteria)
Secondary outcomes
1. Number of joints with active arthritis (JIA score set)
2. Number of joints with limited range of motion (0 to 67)
3. Physician’s global evaluation of disease activity (double-anchored 100-millimetre
VAS)
4. Parent’s global assessment of the child’s overall well-being (double-anchored 100-
millimetre VAS)
5. Disability index (CHAQ)
6. Western ESR
7. Parent’s evaluation of the child’s pain (double-anchored 100-millimetre VAS)
8. Parent’s evaluation of the child’s arthritis (double-anchored 100-millimetre VAS)
9. Child’s assessment of discomfort by facial affective scale (1 to 9 points)
Notes Sources of funding: grant from Boehringer Ingelheim Pharma GmbH & Co. KG,
Biberach, Germany, to the Paediatric Rheumatology International Trials Organisation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “patients were allocated to 1 of the
3 treatment groups in a 1:1:1 randomiza-
tion scheme”
Comment: Randomisation method not
described.
Allocation concealment (selection bias) Unclear risk Comment: No description of allocation
concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “to keep the trial blinded, chil-
dren in the meloxicam group also re-
ceived naproxen placebo suspension and
vice versa, in a double-dummy design”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: Insufficient information
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment:All participantswere accounted
for. Loss to follow-up and withdrawals ex-
plained. However, authors do not report
whether there were significant differences
between completers and non-completers
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Ruperto 2005 (Continued)
Selective reporting (reporting bias) Low risk Comment: All planned outcomes from the
methods were reported in the results
Size Unclear risk Comment: Total participants = 225 (be-
tween 50 and 200 per treatment arm)
Other bias Low risk Comment: No other potential sources of
bias found.
ACR: American College of Rheumatology; CHAQ: Child Health Assessment Questionnaire; ESR: erythrocyte sedimentation rate;
JIA: juvenile idiopathic arthritis; JRA: juvenile rheumatoid arthritis; VAS: visual analogue scale.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Coutinho 1976 Population: adults
Girschick 1999 Allocation: not a randomised controlled trial
Jenkins 1976 Population: adults
Johnsen 1992 Population: adults
Natour 2002 Population: adults
Reicher 1969 Allocation: not a randomised controlled trial
Sadowska-Wroblewska 1980 Population: adults
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D A T A A N D A N A L Y S E S
Comparison 1. Meloxicam versus naproxen
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Participant-reported pain relief
of 30% or greater
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Meloxicam 0.125mg/kg
vs naproxen 10mg/kg
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Meloxicam 0.25mg/kg vs
naproxen 10mg/kg
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Participant-reported pain relief
of 50% or greater
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 Meloxicam 0.125mg/kg
vs naproxen 10mg/kg
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Meloxicam 0.25mg/kg vs
naproxen 10mg/kg
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 2. Celecoxib versus naproxen
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Participant-reported pain relief
of 30% or greater
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Celecoxib 3mg/kg vs
naproxen 7.5mg/kg
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Celecoxib 6mg/kg vs
naproxen 7.5mg/kg
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 3. Rofecoxib versus naproxen
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Participant-reported pain relief
of 30% or greater
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Rofecoxib 0.3 to 12.5mg/
kg vs naproxen 15mg/kg
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Rofecoxib 12.5 to 25mg/
kg vs naproxen 15mg/kg
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Analysis 1.1. Comparison 1 Meloxicam versus naproxen, Outcome 1 Participant-reported pain relief of 30%
or greater.
Review: Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents
Comparison: 1 Meloxicam versus naproxen
Outcome: 1 Participant-reported pain relief of 30% or greater
Study or subgroup Meloxicam Naproxen Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Meloxicam 0.125mg/kg vs naproxen 10mg/kg
Ruperto 2005 46/73 50/78 0.98 [ 0.77, 1.25 ]
2 Meloxicam 0.25mg/kg vs naproxen 10mg/kg
Ruperto 2005 43/74 50/78 0.91 [ 0.70, 1.17 ]
0.01 0.1 1 10 100
Favours naproxen Favours meloxicam
Analysis 1.2. Comparison 1 Meloxicam versus naproxen, Outcome 2 Participant-reported pain relief of 50%
or greater.
Review: Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents
Comparison: 1 Meloxicam versus naproxen
Outcome: 2 Participant-reported pain relief of 50% or greater
Study or subgroup Meloxicam Naproxen Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Meloxicam 0.125mg/kg vs naproxen 10mg/kg
Ruperto 2005 38/73 39/78 1.04 [ 0.76, 1.42 ]
2 Meloxicam 0.25mg/kg vs naproxen 10mg/kg
Ruperto 2005 32/74 39/78 0.86 [ 0.61, 1.22 ]
0.5 0.7 1 1.5 2
Favours naproxen Favours meloxicam
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Analysis 2.1. Comparison 2 Celecoxib versus naproxen, Outcome 1 Participant-reported pain relief of 30%
or greater.
Review: Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents
Comparison: 2 Celecoxib versus naproxen
Outcome: 1 Participant-reported pain relief of 30% or greater
Study or subgroup Celecoxib Naproxen Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Celecoxib 3mg/kg vs naproxen 7.5mg/kg
Foeldvari 2009 53/77 56/83 1.02 [ 0.83, 1.26 ]
2 Celecoxib 6mg/kg vs naproxen 7.5mg/kg
Foeldvari 2009 66/82 56/83 1.19 [ 0.99, 1.43 ]
0.01 0.1 1 10 100
Favours naproxen Favours celecoxib
Analysis 3.1. Comparison 3 Rofecoxib versus naproxen, Outcome 1 Participant-reported pain relief of 30%
or greater.
Review: Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents
Comparison: 3 Rofecoxib versus naproxen
Outcome: 1 Participant-reported pain relief of 30% or greater
Study or subgroup Rofecoxib Naproxen Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Rofecoxib 0.3 to 12.5mg/kg vs naproxen 15mg/kg
Reiff 2006 45/97 48/87 0.84 [ 0.63, 1.12 ]
2 Rofecoxib 12.5 to 25mg/kg vs naproxen 15mg/kg
Reiff 2006 49/90 48/87 0.99 [ 0.76, 1.29 ]
0.01 0.1 1 10 100
Favours naproxen Favours rofecoxib
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A P P E N D I C E S
Appendix 1. Meeting for NIHR Programme Grant agenda on pain in children
Date
Monday 1st June 2015
Location
International Association of the Study of Pain (IASP) Conference, Seattle, USA
Delegates
AllenFinlay, AnnaErskine, BorisZernikow,ChantalWood,Christopher Eccleston, ElliotKrane,GeorgeChalkaiadis,Gustaf Ljungman,
Jacqui Clinch, Jeffrey Gold, Julia Wager, Marie-Claude Gregoire, Miranda van Tilburg, Navil Sethna, Neil Schechter, Phil Wiffen,
Richard Howard, Susie Lord.
Purpose
National Institute for Health Research (NIHR) (UK) Programme Grant - Addressing the unmet need of chronic pain: providing the
evidence for treatments of pain.
Proposal
Nine reviews in pharmacological interventions for chronic pain in children and adolescents: Children (5 new, 1 update, 1 overview, and
2 rapid) self-management of chronic pain is prioritised by the planned NICE guideline. Pain management (young people and adults)
with a focus on initial assessment and management of persistent pain in young people and adults.
We propose titles in paracetamol, ibuprofen, diclofenac, other NSAIDs, and codeine, an overview review on pain in the community,
2 rapid reviews on the pharmacotherapy of chronic pain, and cancer pain, and an update of psychological treatments for chronic pain.
Key outcomes
The final titles: (1) opioids for cancer-related pain (Wiffen 2017a), (2) opioids for chronic non-cancer pain (Cooper 2017a), (3)
antiepileptic drugs for chronic non-cancer pain (Wiffen 2017b), (4) antidepressants for chronic non-cancer pain (Cooper 2017b), (5)
non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain (Eccleston 2017 - this review), (6) non-steroidal anti-
inflammatory drugs (NSAIDs) for cancer-related pain (Cooper 2017c), (7) paracetamol for chronic non-cancer pain (Cooper 2017d).
PICO
Participants : children, aged 3 to 12, chronic pain defined as pain persisting for 3 months (NB: now changed to: birth to 17 years to
include infants, children and adolescents).
Interventions : by drug class including antiepileptic drugs, antidepressants, opioids, NSAIDs, paracetamol.
Comparisons : maintain a separation of cancer and non-cancer, exclude headache, in comparison with placebo and or active control.
Outcomes : we will adopt the IMMPACT criteria.
49Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Appendix 2. Methodological considerations for chronic pain
There have been several recent changes in how the efficacy of conventional and unconventional treatments is assessed in chronic painful
conditions. The outcomes are now better defined, particularly with new criteria for what constitutes moderate or substantial benefit
(Dworkin 2008); older trials may only report participants with ’any improvement’. Newer trials tend to be larger, avoiding problems
from the random play of chance. Newer trials also tend to be of longer duration, up to 12 weeks, and longer trials provide a more
rigorous and valid assessment of efficacy in chronic conditions. New standards have evolved for assessing efficacy in neuropathic pain,
and we are now applying stricter criteria for the inclusion of trials and assessment of outcomes, and are more aware of problems that
may affect our overall assessment. We summarise some of the recent insights that must be considered in this new review.
1. Pain results tend to have a U-shaped distribution rather than a bell-shaped distribution. This is true in acute pain (Moore 2011a;
Moore 2011b), back pain (Moore 2010d), and arthritis (Moore 2010c), as well as in fibromyalgia (Straube 2010); in all cases average
results usually describe the experience of almost no one in the trial. Data expressed as averages are potentially misleading, unless they
can be proven to be suitable.
2. As a consequence, we have to depend on dichotomous results (the individual either has or does not have the outcome) usually
from pain changes or participant global assessments. The Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials
(IMMPACT) group has helped with their definitions of minimal, moderate, and substantial improvement (Dworkin 2008). In
arthritis, trials of less than 12 weeks’ duration, and especially those shorter than eight weeks, overestimate the effect of treatment
(Moore 2010c); the effect is particularly strong for less effective analgesics, and this may also be relevant in neuropathic-type pain.
3. The proportion of patients with at least moderate benefit can be small, even with an effective medicine, falling from 60% with
an effective medicine in arthritis to 30% in fibromyalgia (Moore 2009; Moore 2010c; Moore 2013b; Moore 2014b; Straube 2008;
Sultan 2008). A Cochrane review of pregabalin in neuropathic pain and fibromyalgia demonstrated different response rates for
different types of chronic pain (higher in diabetic neuropathy and postherpetic neuralgia and lower in central pain and fibromyalgia)
(Moore 2009). This indicates that different neuropathic pain conditions should be treated separately from one another, and that
pooling should not be done unless there are good grounds for doing so.
4. Individual patient analyses indicate that patients who get good pain relief (moderate or better) have major benefits in many
other outcomes, affecting quality of life in a significant way (Moore 2010b; Moore 2014a).
5. Imputation methods such as last observation carried forward (LOCF), used when participants withdraw from clinical trials, can
overstate drug efficacy, especially when adverse event withdrawals with drug are greater than those with placebo (Moore 2012).
Appendix 3. MEDLINE search strategy (via Ovid)
1. exp Child/ (1704648)
2. exp Adolescent/ (1771784)
3. (child* or boy* or girl* or adolescen* or teen* or toddler* or preschooler* or pre-schooler*).mp. (2964105)
4. 1 or 2 or 3 (2964105)
5. exp Anti-Inflammatory Agents, Non-Steroidal/ (176717)
6. (aspirin or celecoxib or diclofenac or dipyrone or flurbiprofen, or ibuprofen, or indomet?acin or ketorolac or mefenamic acid or
naproxen or nefopam or phenylbutazone or piroxicam or ketoprofen or nimesulide).mp. (131767)
7. 5 or 6 (205160)
8. exp Pain/ (337664)
9. 4 and 7 and 8 (2485)
10. randomized controlled trial.pt. (428796)
11. controlled clinical trial.pt. (91589)
12. randomized.ab. (324920)
13. placebo.ab. (164048)
14. drug therapy.fs. (1900854)
15. randomly.ab. (228088)
16. trial.ab. (338664)
17. groups.ab. (1434250)
18. 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 (3621582)
19. 9 and 18 (2207)
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Appendix 4. Embase search strategy (via Ovid)
1. exp Child/ (2355146)
2. exp Adolescent/ (1376095)
3. (child* or boy* or girl* or adolescen* or teen* or toddler* or preschooler* or pre-schooler*).mp. (3076161)
4. 1 or 2 or 3 (3533100)
5. exp nonsteroid antiinflammatory agent/ (498156)
6. (aspirin or celecoxib or diclofenac or dipyrone or flurbiprofen, or ibuprofen, or indomet?acin or ketorolac or mefenamic acid or
naproxen or nefopam or phenylbutazone or piroxicam or ketoprofen or nimesulide).mp. (280116)
7. 5 or 6 (515689)
8. exp Pain/ (1005936)
9. 4 and 7 and 8 (10054)
10. crossover-procedure/ (48531)
11. double-blind procedure/ (133820)
12. randomized controlled trial/ (418791)
13. (random* or factorial* or crossover* or cross over* or cross-over* or placebo* or (doubl* adj blind*) or assign* or allocat*).tw.
(1496531)
14. 10 or 11 or 12 or 13 (1582964)
15. 9 and 14 (1645)
Appendix 5. CENTRAL search strategy (via Cochrane Register of Studies Online)
1. MESH DESCRIPTOR Child EXPLODE ALL TREES (203)
2. MESH DESCRIPTOR Adolescent (86514)
3. (child* or boy* or girl* or adolescen* or teen* or toddler* or preschooler* or pre-schooler*):TI,AB,KY (152721)
4. #1 OR #2 OR #3 (152721)
5. MESH DESCRIPTOR Anti-Inflammatory Agents, Non-SteroidalEXPLODE ALL TREES (10470)
6. (aspirin or celecoxib or diclofenac or dipyrone or flurbiprofen, or ibuprofen, or indomet?acin or ketorolac or mefenamic acid or
naproxen or nefopam or phenylbutazone or piroxicam or ketoprofen or nimesulide):TI,AB,KY (17887)
7. #5 OR #6 (28319)
8. MESH DESCRIPTOR Pain EXPLODE ALL TREES (32731)
9. #4 AND #7 AND #8 (939)
Appendix 6. GRADE guidelines
Some advantages of utilising the GRADE process are (Guyatt 2008):
• transparent process of moving from evidence to recommendations;
• clear separation between quality of evidence and strength of recommendations;
• explicit, comprehensive criteria for downgrading and upgrading quality of evidence ratings; and
• clear, pragmatic interpretation of strong versus weak recommendations for clinicians, participants, and policymakers.
The GRADE system uses the following criteria for assigning grade of evidence:
• high: we are very confident that the true effect lies close to that of the estimate of the effect;
• moderate: we are moderately confident in the effect estimate; the true effect is likely to be close the estimate of effect, but there is
a possibility that it is substantially different;
• low: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect;
and
• very low: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the
estimate of effect.
We decreased the grade if there was:
• serious (-1) or very serious (-2) limitation to study quality;
• important inconsistency (-1);
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• some (-1) or major (-2) uncertainty about directness;
• imprecise or sparse data (-1); or
• high probability of reporting bias (-1).
We increased the grade if there was:
• strong evidence of association - significant risk ratio of > 2 (< 0.5) based on consistent evidence from two or more observational
studies, with no plausible confounders (+1);
• very strong evidence of association - significant risk ratio of > 5 (< 0.2) based on direct evidence with no major threats to validity
(+2);
• evidence of a dose response gradient (+1); or
• all plausible confounders would have reduced the effect (+1).
Appendix 7. Summary of efficacy in individual studies
Study Treatment Pain outcome Other efficacy outcomes
Bhettay 1978 Intervention group (N = 15): in-
domethacin (2 weeks) then cross-
over to ketoprofen (2 weeks)
Control group (N = 15): ketopro-
fen (2 weeks) then cross-over to in-
domethacin (2 weeks)
Participants < 20 kg: ketoprofen 25
mg capsule twice daily; participants
> 20 kg: ketoprofen capsules x 2 = 50
mg twice daily
Participants < 20 kg: indomethacin
25 mg capsule twice daily; partici-
pants > 20kg: indomethacin capsules
x 2 = 50 mg twice daily
Study duration: 5 weeks
Participant-reported pain relief of
30% or greater:
no data
Participant-reported pain relief of
50% or greater:
no data
PGIC much or very much im-
proved:
no data
Patient Global Impression of
Change:
no data
Carer Global Impression of
Change:
no data
Requirement for rescue analgesia:
no data
Sleep duration and quality:
no data
Acceptability of treatment:
no data
Physical functioning:
no data
Quality of life:
no data
Brewer 1982 Intervention group (N = 50): feno-
profen 900 mg/m2/d increased to
1800mg/m2/d,maximum3200mg/
d
Control group (N = 49): aspirin
1500 mg/m2/d increased to 3000
mg/m2/d, maximum 5450 mg/d
Study duration: 12 weeks
Participant-reported pain relief of
30% or greater:
≥ 25% improvement
Severity of pain on movement
fenoprofen: 23/50
aspirin: 21/49
Severity of limitation of movement
fenoprofen: 18/50
aspirin: 16/49
Participant-reported pain relief of
50% or greater:
≥ 50% improvement
Severity of pain on movement
fenoprofen: 18/50
aspirin: 15/49
Severity of limitation of movement
Patient Global Impression of
Change:
Patient global assessment of patient
response (satisfactory) to therapy
fenoprofen: 30/50
aspirin: 24/49
Carer Global Impression of
Change:
Parent global assessment of patient
response (satisfactory) to therapy
fenoprofen: 34/50
aspirin: 30/49
Physician global assessment of pa-
tient response
fenoprofen: 31/50
aspirin: 31/49
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(Continued)
fenoprofen: 12/50
aspirin: 12/49
PGIC much or very much im-
proved: no data
Requirement for rescue analgesia:
no data
Sleep duration and quality: no data
Acceptability of treatment: no data
Physical functioning: no data
Quality of life: no data
Foeldvari 2009 Intervention group (N = 77): cele-
coxib 50 mg/5 mL oral suspension
(target dose approximately 3 mg/kg
twice daily)
Intervention group (N = 82): cele-
coxib 100 mg/5 mL oral suspension
(target dose approximately 6 mg/kg
twice daily)
Control group (N = 83): naproxen
125 mg/5 mL oral suspension (target
dose approximately 7.5 mg/kg twice
daily)
Study duration: 12 weeks
Participant-reported pain relief of
30% or greater:
ACR Pediatric-30 responders, n (%)
celecoxib 3 mg/kg: 53/77 (68.8%)
celecoxib 6 mg/kg: 66/82 (80.5%)
naproxen 7.5 mg/kg: 56/83 (67.5%)
Participant-reported pain relief of
50% or greater: no data
PGIC much or very much im-
proved: no data
Patient Global Impression of
Change: no data
Carer Global Impression of
Change:
Parent global assessment of overall
well-being 100-millimetre VAS, least
squares mean change from baseline
(SE)
celecoxib 3 mg/kg: -17.96 (2.42)
celecoxib 6 mg/kg: -20.45 (2.34)
naproxen 7.5 mg/kg: -18.25 (2.33)
Physician global assessment of dis-
ease activity:
100-millimetre VAS, least squares
mean change from baseline (SE)
celecoxib 3 mg/kg: -21.07 (1.86)
celecoxib 6 mg/kg: -23.27 (1.80)
naproxen 7.5 mg/kg: -21.88 (1.79)
Requirement for rescue analgesia:
no data
Sleep duration and quality: no data
Acceptability of treatment: no data
Physical functioning:
Parent assessment of physical func-
tioning, Child Health Assessment
Questionnaire, disability index 0 to
3, least squares mean change from
baseline (SE)
celecoxib 3 mg/kg: -0.28 (0.05)
celecoxib 6 mg/kg: -0.32 (0.05)
naproxen 7.5 mg/kg: -0.31 (0.05)
Quality of life: Pediatric Quality of
Life Inventory
All treatment groups improved Pedi-
atricQuality of Life Inventory scores.
Scores of participants in the cele-
coxib 6 mg/kg twice-daily group
or naproxen 7.5 mg/kg twice-daily
group were higher than those of par-
ticipants in the celecoxib 3 mg/kg
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twice-daily group, but results were
non-significant (data not shown in
publication). Unclear whether differ-
ences are between groups or over time
celecoxib 3 mg/kg: no data
celecoxib 6 mg/kg: no data
naproxen 7.5 mg/kg: no data
Giannini 1990 Intervention group (N = 45):
ibuprofen suspension (concentration
100 mg/5mL) + placebo aspirin
Control group (N = 47): aspirin
200 mg tablet (participant weight 10
to 30 kg) or 300 mg capsules (par-
ticipant weight > 30 kg) + placebo
ibuprofen
Week 2: physician’s option to increase
dose to 40 mg/kg/day ibuprofen or
80 mg/kg/day aspirin, provided no
significant side effects
Study duration: 12 weeks
Participant-reported pain relief of
30% or greater: no data
Participant-reported pain relief of
50% or greater: no data
PGIC much or very much im-
proved:
PatientGlobal Impression of Change
very much improved:
ibuprofen: 22/26 (85%)
aspirin: 18/20 (90%)
Carer Global Impression of Change:
ibuprofen: 33/42 (79%)
aspirin: 29/35 (83%)
Investigator Global Evaluation:
ibuprofen: 34/44 (78%)
aspirin: 27/35 (77%)
Patient Global Impression of
Change:
ibuprofen: 22/26 (85%)
aspirin: 18/20 (90%)
Carer Global Impression of
Change:
ibuprofen: 33/42 (79%)
aspirin: 29/35 (83%)
Investigator Global Evaluation:
ibuprofen: 34/44 (78%)
aspirin: 27/35 (77%)
Requirement for rescue analgesia:
no data
Sleep duration and quality: no data
Acceptability of treatment: no data
Physical functioning: no data
Quality of life: no data
Moran 1979 Intervention group (N = 23):
naproxen 10 mg/kg/24 hrs given as a
suspension in 2 divided doses
Control group (N = 23): aspirin sol-
uble 80 mg/kg/day, divided into 4
doses
Study duration: 2 x 4 weeks
Participant-reported pain relief of
30% or greater: no data
Participant-reported pain relief of
50% or greater: no data
PGIC much or very much im-
proved: no data
Patient Global Impression of
Change: no data
Carer Global Impression of
Change: no data
Requirement for rescue analgesia:
no data
Sleep duration and quality: no data
Acceptability of treatment:
Medication preference at end of trial:
Naproxen much better: 0
Naproxen better: 9
Both periods equal: 9
Aspirin better: 4
Aspirin much better: 1
Physical functioning: no separate
data
Quality of life: no data
Reiff 2006 Intervention group (N = 209):
(children) LD rofecoxib 0.3mg/kg/
day maximum 12.5mg/day, or HD
rofecoxib 0.6mg/kg/day maximum
25 mg/day; (adolescents) rofecoxib
Participant-reported pain relief of
30% or greater:
ACR Pedi 30% reduction
LD rofecoxib: 45/97 (46.2%)
HD rofecoxib: 49/90 (54.5%)
Patient Global Impression of
Change: no data
Carer Global Impression of
Change: no data
Patient/Parent Global Assessment
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12.5 or 25 mg daily
Control group (N = 101): (chil-
dren) naproxen 15 mg/kg/day 5 mg
oral suspension; (adolescents) 15mg/
kg/day maximum 1000 mg/day
Study duration: 12 weeks
naproxen: 48/87 (55.1%)
Participant-reported pain relief of
50% or greater: no data
PGIC much or very much im-
proved: no data
of Pain:
mean change from baseline (95% CI)
LD rofecoxib: -12.50 (-15.98; -9.02)
HD rofecoxib: -13.12 (-16.75; -9.
48)
naproxen: -8.43 (-11.98; -4.88)
Requirement for rescue analgesia:
no data
Sleep duration and quality: no data
Acceptability of treatment: no data
Physical functioning:
CHAQ index: mean change from
baseline (95% CI)
LD rofecoxib: -0.11 (-0.18; -0.05)
HD rofecoxib: -0.15 (-0.21; -0.08)
naproxen: -0.12 (-0.18; -0.05)
Quality of life:
Patient/parent assessment of overall
well-being:mean change from baseline
(95% CI) (proportion of improvement
from baseline)
LD rofecoxib: -11.57 (-14.78; -8.36)
(74.3%)
HD rofecoxib: -12.08 (-15.44; -8.
73) (76%)
naproxen: -8.56 (-11.85; -5.27)
(73%)
Additional data
Investigators’ global assessment of
disease activity: mean change from
baseline (95% CI)
LD rofecoxib: -12.45 (-14.95; -9.94)
HD rofecoxib: -13.27 (-15.88; -10.
65)
naproxen: -12.05 (-14.60; -9.50)
Ruperto 2005 Intervention group 1 (N = 73): LD
meloxicam 0.125 mg/kg, 1 dose per
day
Intervention group 2 (N = 74):HD
meloxicam 0.25 mg/kg, 1 dose per
day
Control group (N = 78): naproxen
5 mg/kg, twice per day
Study duration: 48 weeks
Participant-reported pain relief of
30% or greater:
@ 3 MONTHS
LD meloxicam: 46/73 (63%), 95%
CI 52 to 74%
HD meloxicam: 43/74 (58%), 95%
CI 47 to 69%
naproxen: 50/78 (64%), 95% CI 53
to 75%
@ 12 MONTHS
LD meloxicam: 56/73 (77%), 95%
CI 67 to 86%
HD meloxicam: 56/74 (76%), 95%
Patient Global Impression of
Change: no data
Participant reported assessment of
discomfort (facial affective scale 1
to 9 points):
@ 3 MONTHS
LD meloxicam: 0.3 ± 0.2
HD meloxicam: 0.4 ± 0.2
naproxen: 0.3 ± 0.2
@ 12 MONTHS
LD meloxicam: 0.3 ± 0.2
HD meloxicam: 0.3 ± 0.2
naproxen: 0.2 ± 0.2
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CI 66 to 85%
naproxen: 58/78 (74%), 95% CI 65
to 84%
Participant-reported pain relief of
50% or greater:
@ 3 MONTHS
LD meloxicam: 38/73 (52%), 95%
CI 41 to 64%
HD meloxicam: 32/74 (43%), 95%
CI 32 to 55%
naproxen: 39/78 (50%), 95% CI 39
to 61%
@ 12 MONTHS
LD meloxicam: 50/73 (68%), 95%
CI 58 to 79%
HD meloxicam: 48/74 (65%), 95%
CI 54 to 76%
naproxen: 53/78 (68%), 95% CI 58
to 78%
TOTAL POOLING: P = 0.7
PGIC much or very much im-
proved: no data
Physician global impression of dis-
ease activity (VAS 0 to 100):
@ 3 MONTHS
LD meloxicam: 19.4 ± 20.7
HD meloxicam: 20.6 ± 20.3
naproxen: 21.1 ± 19.2
@ 12 MONTHS
LD meloxicam: 15.4 ± 20.5
HD meloxicam: 16.8 ± 19.0
naproxen: 14.4 ± 16.7
Carer Global Impression of Pain
(VAS 0 to 100):
@ 3 MONTHS
LD meloxicam: 17.6 ± 20.2
HD meloxicam: 21.9 ± 23.6
naproxen: 20.8 ± 22.4
@ 12 MONTHS
LD meloxicam: 13.4 ± 17.6
HD meloxicam: 17.2 ± 22.5
naproxen: 15.9 ± 21.3
Requirement for rescue analgesia:
no data
Sleep duration and quality: no data
Acceptability of treatment: no data
Physical functioning:
CHAQDisability Index (0 to 3 points)
@ 3 MONTHS
LD meloxicam: 0.4 ± 0.5
HD meloxicam: 0.5 ± 0.6
naproxen: 0.5 ± 0.6
@ 12 MONTHS
LD meloxicam: 0.3 ± 0.4
HD meloxicam: 0.4 ± 0.6
naproxen: 0.3 ± 0.5
Quality of life: no data
ACR:American College of Rheumatology;CI: confidence interval;HD: high-dose; LD: low-dose;N: number of participants; PGIC:
Patient Global Impression of Change;SE: standard error; VAS: visual analogue scale
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Appendix 8. Summary of adverse events and withdrawals in individual studies
Study Treatment Adverse events Withdrawals
Bhettay 1978 Intervention group (N = 15): in-
domethacin (2 weeks) then cross-
over to ketoprofen (2 weeks)
Control group (N = 15): ketopro-
fen (2 weeks) then cross-over to in-
domethacin (2 weeks)
Participants < 20 kg: ketoprofen 25
mg capsule twice daily; participants
> 20 kg: ketoprofen capsules x 2 = 50
mg twice daily
Participants < 20 kg: indomethacin
25 mg capsule twice daily; partici-
pants > 20kg: indomethacin capsules
x 2 = 50 mg twice daily
Study duration: 5 weeks
Total adverse events occurring
(may be more than 1 per partici-
pant):
ketoprofen: 9/30
indomethacin: 9/30
No. participants reporting an ad-
verse event:
ketoprofen: 9/30
indomethacin: 9/30
Serious adverse events:
ketoprofen: 0/30
indomethacin: 0/30
Specific adverse events:
ketoprofen; indomethacin
loss of appetite: 1/30; 1/30
nausea: 1/30; 2/30
vomiting: 3/30; 2/30
abdominal pain: 3/30; 2/30
frank blood in stool: 0/30; 1/30
headache: 1/30; 1/30
Total all-cause withdrawals:
ketoprofen: 0/30
indomethacin: 0/30
(1 disqualified for non-compliance,
not withdrawn)
Withdrawals due to adverse events:
ketoprofen: 0/30
indomethacin: 0/30
Brewer 1982 Intervention group (N = 50): feno-
profen 900 mg/m2/d increased to
1800mg/m2/d,maximum3200mg/
d
Control group (N = 49): aspirin
1500 mg/m2/d increased to 3000
mg/m2/d, maximum 5450 mg/d
Study duration: 12 weeks
Total adverse events occurring
(may be more than 1 per partici-
pant):
fenoprofen: n = 78
aspirin: n = 90
No. participants reporting an ad-
verse event:
fenoprofen: 28/49
aspirin: 40/50
Serious adverse events:
fenoprofen: 0/79
aspirin: 0/50
Specific adverse events:
fenoprofen (n = 49); aspirin (n = 50)
abdominal pain: 9; 10
stomach discomfort: 12; 9
diarrhoea: 4; 2
vomiting: 2; 9
nausea: 2; 3
nausea and vomiting: 0; 2
general gastrointestinal upset: 0; 2
constipation: 3; 8
anorexia: 2; 3
occult blood in stool: 0; 2
Total all-cause withdrawals:
fenoprofen: 2/49 (4%); noncompli-
ance (1); difficulty swallowing tablet
(1)
aspirin: 10/50 (20%); adverse effects
(7); inefficacy (1); failed to co-operate
(1); wrong assignment chose to discon-
tinue (1)
Withdrawals due to adverse events:
fenoprofen: 0/49 (0%)
aspirin: 7/50 (14%)
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cramps, abdominal: 2; 3
diplopia: 5; 0
dizziness: 0; 2
headache: 4; 2
rash: 6; 2
fatigue: 0; 2
chills: 0; 2
hyperventilation:1; 2
SGOT increase: 0; 7
SGPT increase: 0; 6
Foeldvari 2009 Intervention group (N = 77): cele-
coxib 50 mg/5 mL oral suspension
(target dose approximately 3 mg/kg
twice daily)
Intervention group (N = 82): cele-
coxib 100 mg/5 mL oral suspension
(target dose approximately 6 mg/kg
twice daily)
Control group (N = 83): naproxen
125 mg/5 mL oral suspension (target
dose approximately 7.5 mg/kg twice
daily)
Study duration: 12 weeks
Total adverse events occurring
(may be more than 1 per partici-
pant):
celecoxib 3 mg/kg: 49/77 (63.6%)
celecoxib 6 mg/kg: 57/82 (69.5%)
naproxen 7.5 mg/kg: 60/83 (72.3%)
No. participants reporting an ad-
verse event:
no data
Serious adverse events:
celecoxib 3 mg/kg: 3/77
celecoxib 6 mg/kg: 2/82
naproxen 7.5 mg/kg: 0/83
Specific adverse events:
Significant AEs: skin and subcuta-
neous tissue disorders (celecoxib 6
mg; 6/82 (7.3%; P ≤ 0.10)
Others AEs: eye disorders; headache
(reported most often); gastrointesti-
nal disorders; general disorders and
administration site conditions; in-
fections and infestations; injury and
poisoning; investigations; muscu-
loskeletal, connective tissue, and
bone disorders; nervous system dis-
orders; respiratory, thoracic, and me-
diastinal disorders
Total all-cause withdrawals:
celecoxib 3 mg/kg: 10/77
celecoxib 6 mg/kg: 11/82
naproxen 7.5 mg/kg: 9/83
Withdrawals due to adverse events:
celecoxib 3 mg/kg: 3/77
celecoxib 6 mg/kg: 7/82
naproxen 7.5 mg/kg: 3/83
Giannini 1990 Intervention group (N = 45):
ibuprofen suspension (concentration
100 mg/5 mL) + placebo aspirin
Control group (N = 47): aspirin
200 mg tablet (participant weight 10
to 30 kg) or 300 mg capsules (par-
ticipant weight > 30 kg) + placebo
ibuprofen
Week 2: physician’s option to increase
dose to 40 mg/kg/day ibuprofen or
Total adverse events occurring
(may be more than 1 per partici-
pant):
ibuprofen: unclear
aspirin: unclear
No. participants reporting an ad-
verse event:
ibuprofen: 40/45
aspirin: 44/47
Serious adverse events:
Total all-cause withdrawals:
ibuprofen: 1/45
aspirin: 9/47
Withdrawals due to adverse events:
ibuprofen: 0/45
aspirin: 6/47
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80 mg/kg/day aspirin, provided no
significant side effects
Study duration: 12 weeks
ibuprofen: 4/45
aspirin: 13/47
Specific adverse events:
ibuprofen; aspirin
abnormalities in liver function: 1/45;
22/47; P < 0.01
digestive system adverse effects: 19/
45; 33/47
elevated liver enzyme values: 0/45; 5/
47
abdominal pain: 0/45; 1/47
positive stool test result: 8/45; 15/47
positive faecal occult blood tests: 2/
45; 1/47
Moran 1979 Intervention group (N = 23):
naproxen 10 mg/kg/24 hrs given as a
suspension in 2 divided doses
Control group (N = 23): aspirin sol-
uble 80 mg/kg/day, divided into 4
doses
Study duration: 2 x 4 weeks
Total adverse events occurring
(may be more than 1 per partici-
pant):
naproxen: 10/23
aspirin: 2/23
No. participants reporting an ad-
verse event:
naproxen: 6/23
aspirin: 1/23
Serious adverse events:
naproxen: 0/23
aspirin: 0/23
Specific adverse events:
naproxen:
1 - abdominal pain
aspirin:
1 - abnormal liver test, nausea, tinni-
tus, and lassitude;
1 - abnormal liver test;
1 - vomiting
Total all-cause withdrawals:
naproxen: 1/23 (abdominal pain)
aspirin: 3/23 (1 - abnormal liver test,
nausea, tinnitus, and lassitude; 1 - ab-
normal liver test; 1 - vomiting)
Withdrawals due to adverse events:
naproxen: 1/23
aspirin: 3/23
Reiff 2006 Intervention group (N = 209):
(children) LD rofecoxib 0.3mg/kg/
day maximum 12.5mg/day, or HD
rofecoxib 0.6mg/kg/day maximum
25 mg/day; (adolescents) rofecoxib
12.5 or 25 mg daily
Control group (N = 101): (chil-
dren) naproxen 15 mg/kg/day 5 mg
oral suspension; (adolescents) 15mg/
kg/day maximum 1000 mg/day
Study duration: 12 weeks
Total adverse events occurring
(may be more than 1 per partici-
pant):
no data
No. participants reporting an ad-
verse event:
LD rofecoxib: 21/109 (19.3%)
HD rofecoxib: 22/100 (22%)
naproxen: 28/101 (27.7%)
Serious adverse events:
LD rofecoxib: 0/109
HD rofecoxib: 0/100
naproxen: 0/101
Total all-cause withdrawals:
LD rofecoxib: 10/109
HD rofecoxib: 5/100
naproxen: 10/101
Withdrawals due to adverse events:
LD rofecoxib: 3/109 (0.03%)
HD rofecoxib: 0/100 (0.0%)
naproxen: 3/101 (0.03%)
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Specific adverse events:
Most common AEs, > 5% in each
group: (n) LD rofecoxib; HD rofe-
coxib; naproxen
abdominal pain: 7/109; 6/100; 13/
101
headache: 6/109; 5/100; 13/101
upper abdominal pain: 7/109; 12/
100; 7/101
nasopharyngitis: 11/109; 10/100; 1/
101
pyrexia: 5/109; 4/100; 9/101
diarrhoea: 5/109; 7/100; 4/101
pharyngitis: 7/109; 3/100; 3/101
vomiting: 7/109; 3/100; 3/101
upper respiratory tract infection: 6/
109; 6/100; 7/101
nausea: 3/109; 4/100; 6/101
Ruperto 2005 Intervention group 1 (N = 73): LD
meloxicam 0.125 mg/kg, 1 dose per
day
Intervention group 2 (N = 74):HD
meloxicam 0.25 mg/kg, 1 dose per
day
Control group (N = 78): naproxen
5 mg/kg, twice per day
Study duration: 48 weeks
Total adverse events occurring
(may be more than 1 per partici-
pant):
LD meloxicam: n = 209
HD meloxicam: n= 229
naproxen: n = 247
No. participants reporting an ad-
verse event:
LD meloxicam: 54/73 (74%)
HD meloxicam: 59/74 (80%)
naproxen: 66/78 (85%)
Considered to be drug related:
LD meloxicam: 7/73 (10%)
HD meloxicam: 11/74 (15%)
naproxen: 10/78 (13%)
Serious adverse events:
LD meloxicam: 4/73 (5%)
HD meloxicam: 7/74 (9%)
naproxen: 10/78 (13%)
Specific adverse events:
LD meloxicam (n = 73); HD meloxi-
cam (n = 74); naproxen (n = 79)
eye disorders: 5; 6; 8
gastrointestinal disorders: 28; 27; 25
paindiarrhoea, nausea, vomiting: 21;
19; 19
pharyngolaryngeal pain: 9; 5; 4
general disorders: 13; 14; 19
pyrexia: 11; 13; 14
Total all-cause withdrawals:
LD meloxicam: n = 15/73 (21%).
LTFU (0); AE (7); lack of efficacy (2)
; other (4); others (2)
HD meloxicam: n = 11/74 (15%).
LTFU (0); AE (3); lack of efficacy (1)
; other (5); others (2)
naproxen: n = 17/78 (22%). LTFU
(0); AE (10); lack of efficacy (3);
other (4); others (0)
Withdrawals due to adverse events:
LD meloxicam: 7/73 (9.6%)
HD meloxicam: 3/74 (4.1%)
naproxen: 10/78 (12.8%)
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(Continued)
infections and infestations: 30; 38;
39
nasopharyngitis: 4; 9; 7
physical examination: 9; 6; 4
musculoskeletal and connective tis-
sue disorders: 11; 22; 10
nervous system disorders: 10; 11; 7
headache not otherwise specified: 9;
10; 5
respiratory, thoracic, andmediastinal
disorders: 22; 19; 26
cough: 7; 9; 14
rhinitis not otherwise specified: 13;
11; 16
skin and subcutaneous tissue disor-
ders: 4; 5; 13
eczema, erythema, pruritus, rash: 0;
3; 8
bleeding disorders (rectal
haemorrhage, epistaxis, haematuria,
haematoma,Henoch-Schonlein pur-
pura): 3; 2; 9
AE: adverse event;HD: high-dose; LD: low-dose; LTFU: long-term follow-up; N: number of participants; SGOT: serum glutamate-
oxaloacetic transaminase; SGPT: serum glutamate-pyruvate transaminase
WH A T ’ S N E W
Date Event Description
14 August 2017 Amended References for some reviews from the suite amended to reflect correct publication Issue
H I S T O R Y
Date Event Description
20 February 2017 Amended References for cancer pain protocols updated.
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C O N T R I B U T I O N S O F A U T H O R S
TC and CE registered the title.
TC, Phil Wiffen, and CE wrote the template protocol for the suite of children’s reviews of which this review is a part.
All authors contributed to writing the protocol, and all authors agreed on the final version.
All authors were responsible for data extraction, analysis, and writing of the Discussion for the full review.
All authors will be responsible for the completion of updates.
D E C L A R A T I O N S O F I N T E R E S T
CE: none known.
TC: none known.
BA: none known; BA is a specialist anaesthetist and intensive care physician and manages the perioperative care of children requiring
surgery and those critically ill requiring intensive care.
EF: none known.
NW: none known; NW is a specialist paediatric rheumatologist and treats patients with chronic pain.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• National Institute for Health Research (NIHR), UK.
NIHR Programme Grant, Award Reference Number: 13/89/29 (Addressing the unmet need of chronic pain: providing the evidence
for treatments of pain)
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We did not consider studies with fewer than 10 participants per treatment arm for inclusion in this review, as is standard practice for
this group.
Data were insufficient for pooled analyses comparing one drug to another, so we chose to do a post hoc analysis using the randomised
cohorts of NSAIDs to calculate the mean response rate for any NSAID at any dose.
62Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Anti-Inflammatory Agents, Non-Steroidal [adverse effects; ∗therapeutic use]; Arthritis, Juvenile [∗drug therapy]; Arthritis, Rheumatoid
[∗drug therapy]; Aspirin [adverse effects; therapeutic use]; Celecoxib [adverse effects; therapeutic use]; Chronic Disease; Chronic Pain
[∗drug therapy]; Fenoprofen [adverse effects; therapeutic use]; Ibuprofen [adverse effects; therapeutic use]; Lactones [adverse effects;
therapeutic use]; Methoxsalen [adverse effects; therapeutic use]; Naproxen [adverse effects; therapeutic use]; Randomized Controlled
Trials as Topic; Sulfones [adverse effects; therapeutic use]; Thiazines [adverse effects; therapeutic use]; Thiazoles [adverse effects;
therapeutic use]
MeSH check words
Adolescent; Child; Child, Preschool; Humans
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